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Astrogliosis is induced by neuronal damage and is also a pathological feature of the 
major aging-related neurodegenerative disorders. The mechanisms that control the 
cascade of astrogliosis have not been well established. In a previous study, we 
identified a novel androgen receptor (AR)-interacting protein (p44/WDR77) and found 
that it plays a critical role in the control of proliferation and differentiation of prostate 
epithelial cells. In the present study, we found that deletion of the p44 gene in the 
mouse brain caused accelerated aging with dramatic astrogliosis. The p44/WDR77 is 
expressed in astrocytes and loss of p44/WDR77 expression in astrocytes leads to 
astrogliosis. Our results reveal a novel role of p44/WDR77 in astrocytes, which may 
explain the well-documented role of androgens in suppression of astrogliosis. 
While many of detailed mechanisms of astrocyte activation remain to be 
elucidated, a number pathways have been implicated in astrocyte activation including 
p21Cip1 and the NF-B pathway. Astrocytic activation induced by p44/WDR77 gene 
deletion was associated with a significant increase of p21Cip1 expression and NF-B 
activation characterized by p65 nuclear localization. We found that down-regulation of 
p21Cip1 expression inhibited astrocyte activation induced by the p44/WDR77 deletion 
and was accompanied by a decreased p65 nuclear localization. While p21Cip1 role in 
 vi
astrocyte activation and NF-B activation is not well understood, studies of other cell 
cycle regulators have implicated cell cycle control systems as modulators of astrocyte 
activation, thus p21Cip1 could induce secondary effect to induce p65 nuclear localization. 
However, p65 knockdown completely relieved the inhibition of astrocyte growth induced 
by the p44/WDR77 deletion, while p21Cip1 knockdown only partially recovered this 
inhibition.  Thus, NF-B activity performs additional regulatory actions not mediated by 
p21Cip1. These analyses imply that p4/WDR77 suppresses astrocyte activation through 
modulating p21Cip1 expression and NF-B activation. 
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Chapter I: Introduction 
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A. Central nervous system (CNS): 
The nervous system is an organ system that exemplifies a masterpiece of 
biologic function from its molecular and cellular elements to its behavioral and cognitive 
elements. The extraordinary nervous tissue that innervates the human body was initially 
described and examined by the ancient Egyptians, Greeks, and Romans (1). However, 
it was not until the mid-twentieth century, with the advent of electron microscopy, that 
neuroscientists began to perceive the nervous system as a uniform tissue, flowing 
continuously together but composed of cellular units (2). Histological research by Italian 
neuropathologist Camillo Golgi, Spanish neuroanatomist Santiago Ramony Cajal and a 
cohort of others led to a categorization of a nervous system divided into two broad 
groups of cells, neurons and neuroglia. These groups of cells forge a neural network 
that transduces electrophysiological and molecular processes sent throughout the body 
(2, 3). The innervations and processes of these networks constitute one of three major 
functional areas: sensory, motor, and associational. The sensory networks incorporate 
information from both the environment (external) and the body itself (internal). Upon this 
incorporation the sensory networks then transmit this information on for higher level 
processing. The motor networks act to direct temporal and spatial muscular 
contractions, thereby coordinating the grace of movement. Finally the associational 
networks integrate the processes of the other networks to generate cognitive action.  In 
this way the associational network modes act as hubs for complex cognitive processes 
forming the foundations for emotions, cognition, and other complex brain functions (3).  
From an anatomical point of view, neuroscientists have divided the human nervous 
system into two large systems, peripheral and central. The peripheral nervous system 
(PNS) arises from sensory and motor ganglia integrated with the motor and sensory 
neurons.  Innervations spread from these ganglia throughout the body. The central 
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nervous system (CNS), then, is subdivided into two large complex components, the 
brain and spinal cord (3).    
 
AI. Structural Subdivision of the CNS: 
The CNS is the neural architecture which incorporates environmental signals- 
both internal and external perceived by innervating sensory neurons and with a dynamic 
and unique response. This diverse and dynamic system arises from four principal parts: 
the spinal cord, hindbrain, midbrain, and forebrain.  Amidst the subdivisions of the brain 
flow four fluid-filled cerebral ventricles, a pair of lateral ventricles and, in the midline, the 
third and fourth ventricle. The pons, cerebellum and medulla together create the 
hindbrain or rhombencephalon. The hindbrain with the midbrain or mesencephalon (or 
midbrain) forge from the tectum, and tegmentum, form the brainstem which joins and is 
structurally continuous with the spinal cord. The diencephalons with the cerebral 
hemispheres collectively give rise to the forebrain (4). Together all four of these parts 
cooperate and coordinate to create a diverse and dynamic system of informational input 
and processing.  
 
AI (i). Brainstem: 
The brainstem transduces information to and from the forebrain for a multitude 
of primary sensory and motor pathways essential to human health and disease. The 
corticospinal tract is a bundle of primarily motor axons that travels along the brainstem. 
This tract transducing through medial lemniscus of the brainstem the posterior column-
medial lemniscus pathway facilitates vibration sensation and fine touch. Adjacent to 
these pathways the spinothalamic tract transmits signals stimulated by crude touch, 
pain, and temperature. From the surface of the brainstem emerge ten of the twelve 
cranial nerves in humans providing the primary sensory and motor innervation to the 
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face and neck.  Additionally the brainstem is home to an array of nuclei critical to a 
myriad of vital functions including control of cardiac output, respiration, circadian rhythm 
and level of consciousness (5-7). Finally and perhaps the most striking structure of the 
brainstem is the cerebellum, described early by Aristotle and the anatomist Galen (1).  
While its role has not been completely elucidated, the cerebellum has been implicated 
in a number of cognitive and emotional functions, such as language and fear regulation 
(6). However, what has been firmly established is the cerebellum’s ability to integrate 
sensory input with fine motor activity to facilitate graceful coordination, in order to 
enhance the learning of motor tasks (7). These pathways and structures help facilitate 
bidirectional communication between the brain and periphery (3).     
 
AI (ii). Diencephalon: 
The forebrain is comprised of five subdivisions: the subthalamus, hypothalamus, 
thalamus and epithalamus which together form the diencephalon and the telencephalon 
or cerebrum (4). While the subthalamus is believed to have functional interconnections 
with the basal ganglia with implication in mediating skeletal muscle movement, its 
overall function still remains to be elucidated (8, 9). The epithalamus acts as a conduit 
between the limbic system and other areas of the neural cortex (10). Located between 
the cerebral cortex and midbrain in humans the thalamus relays gustatory, auditory, 
visceral, somatic, and visual systems sensory information to the telencephalon. The 
thalamus has a multitude of other functional implications including relaying motor 
signals and modulating circadian function (11, 12). The hypothalamus creates a 
dynamic interplay between the nervous system and endocrine system that provides 
regulatory control over an array of homeostatic mechanisms. This interplay is directed 
by the synthesis and secretion of neurohormones, hypothalamic releasing hormones, 
which act on the pituitary to stimulate the release of regulatory hormones (13). This 
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interplay illustrates the diencephalons ability to act as a medium for transmission of 
information between other biological systems such as the endocrine, and immune 
systems, and the higher brain functions orchestrated telencephalon or cerebrum (3).  
 
AI (iii). Telencephalon: 
The most notable features of the cerebrum are the cerebral hemispheres with 
their gyri, or ridges of folded cortical tissue, surrounded by sulci, the depressions or 
fissures that separate the gyri. These gyral and sulcal patterns divide the hemispheres 
into four lobes occipital, temporal, parietal, and frontal-- named after the underlining 
cranial bones. The precentral and postcentral gyri which contain primary motor cortex 
and primary somatic sensory cortex respectively are divided by the central sulcus which 
runs between the frontal and parietal lobes of the cerebral hemispheres. Additional 
subdivisions of the telencephalon are the basal ganglia, hippocampus and amygdala. 
The basal ganglia are a collection of interwoven subcortical nuclei embedded deeply 
within the cerebrum. This interwoven network of subcortical nuclei dynamically connects 
the cerebral cortex, thalamus and other cortical areas, with functional involvement in 
motor and cognitive processes. Located inside the medial temporal lobes the 
hippocampus is a prominent member of the limbic system that has been described as 
looking like a sea horse. The hippocampus provides a critical role for the process of 
behavioral inhibition, memory and spatial navigation. The amygdala, a fellow 
component of the limbic system like the hippocampus, is located within the medial 
temporal lobes. The amygdala has been shown to conduct key functions in emotional 
learning and memory (14, 15). These processes further illustrates that the 
telencephalon or cerebrum with vast diversity and complexity is the origin of the 
extraordinary process that form what we view as cognition (3).  This being said, a much 
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deeper understanding of its beauty and complexity as it relates to human health and 
disease lies in the molecular mechanisms of its cellular components (16). 
 
AII. Cellular Composition of the CNS: 
AII (i). Neurons: 
There are more than 100 billion neurons that innervate the human brain. These 
neurons utilize electrical and chemical signaling mechanisms to monitor changes in the 
environment, process these changes and in doing so facilitate the appropriate 
responses. A neuron is composed of a cell body or perikaryon, containing the nucleus 
and cytoplasmic organelles, from which a signaling process or axon extends as axonal 
branching. Growing out from the perikaryon are varying number of ornate branches or 
dendrites that form connections with the perikaryons and axons of other neurons.  The 
grey matter of the CNS, which directs sensory or motor stimulus to interneurons, 
generates a response to the stimulus through chemical synaptic activity arising from 
neuronal cell bodies. Synaptic activity from the grey matter pulses down the axons, 
many of which are insulated with myelin sheaths that forge the white matter. Although 
this fundamental cellular organization is shared among most neurons, they are 
distinguished by specializations in sizes and shapes which reflect their diverse functions 
in the networks in which they reside (16).     
Elaborate dendritic branching from the perikaryon facilitates the potential 
diversity of multitudinous signals, by creating a vast area by which afferents can be 
received. As expected the complexity of the dendritic arbor greatly influences the 
number of synaptic inputs a given neuron can receive. This complexity is illustrated in 
nerves cell lacking dendrites, which may have from only one to a few synaptic inputs. 
The vital ornate branching of dendrites is maintained by a graceful interplay between 
cytoskeletal elements and adhesion molecules.  Additional dendrites are marked by 
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high numbers of ribosomes, which aid in the integration signals from other neurons. 
From the dendrites and the perikaryon, electric and chemical signals are transduced 
down the neuronal axon to other neurons (16).  
The synaptic connections between axons and dendrites, or less often between 
axon and perikaryon, are composed of a presynaptic terminal, in most cases a synaptic 
cleft, and the postsynaptic specialization of the target cell. The presynaptic terminals 
arise from distal terminations of the branches of an axon with an elaborate secretory 
apparatus adjacent to a postsynapic target (16). Extracellular proteins such as S-
laminin assemble in the synaptic cleft to influence the binding, diffusion, and 
degradation of molecules released by from presynaptic terminal (17). With the aid of a 
complex of cytoskeleton proteins the postsynaptic specialization consolidates and 
coordinates neurotransmitter receptors to modulate the response to neurotransmitters 
flowing into the synaptic cleft. These neurotransmitters released by synaptic vesicles in 
the synaptic cleft, bind to their receptors ignite synaptic activation at the postsynaptic 
specialization which pulses the signal down the axon to its target cell (16).  
A self-regenerating wave of electrical activity know as the action potential which 
transduces the synapse initiates in a swelling or axon hillock that leaves the perikaryon  
traveling into the axon to form synaptic connections with other neurons. The synaptic 
connections made by axons help to mold its morphology and the path it navigates 
through the nervous system. This is illustrated by the often unmyelinated axons, and the 
relatively simple morphology of axons that extend from local interneurons or circuit 
neurons, contrary to the frequently myelinated axons of neurons with connections to a 
multitude of areas of the nervous system (16). These synapses create a symphony of 
electrical activity which gives rise to a vast amount of neural communication that directs 
many of the nervous systems actions critical to human health and disease. However the 
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neurons which generate these signals are not the components in the formation of 
human cognition (3).  
 
AII (ii). Neuroglial cells: 
Neuroglial cells or glia were once regarded as the glue that maintains the 
architecture of the CNS, but now these cells are appreciated for a broad array of 
functions (18). These formerly under-appreciated cells comprise ninety percent of the 
cells in the human brain, greatly outnumbering the neurons (19, 20). Functions for glial 
cells have been established in a multitude of diverse that vital neural mechanisms. 
These critical roles are illustrated in neuroglia’s abilities to maintain a healthy synaptic 
environment by modulating ion and neurotransmitters concentrations at or near the 
synapse (21, 22), enhancing the rate of signal transduction by insulating neurons with 
myelin (23). Additionally neuroglia provides the bases for immune response in the CNS 
(24). With such vast implications in every aspect of nervous system function that has 
only gained recognition within the past few decades, research into the molecular 
mechanisms of neuroglial cells represents an immense well of information that can aid 
in care for human health and diseases (18). 
The glue or glia of the CNS of adult humans is composed of three major cell 
types:  astrocytes named for their star-like appearance, oligodendrocytes, and microglia 
(18, 23, 25, 26). Astrocytes have a vast array of functions, many of which will be 
discussed in greater detail later, but a few of which are the regulation of extracellular 
concentrations of ions, and transmitters (21 and 22), modulation of cerebral blood flow 
(27), and enhancement of neuronal and synaptic function (28 and 29). 
Oligodendrocytes enhance the speed of signal  transduction by insulating axons in lipid-
rich myelin, leaving  unmyelinated areas know as nodes of Ranvier by which the action 
potentials travel (23). Astrocytes and oligodendrocytes, commonly referred to as 
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macroglia, unlike microglia are derived from ectodermal tissue, and in particular the 
neural tube, giving them roles in early neural development (18, 19, 23) 
Microglia, arising largely from hematopoietic precursor cells, comprising five to 
ten percent of the glial population in the human CNS. These cells of hematopoietic 
origin function, when activated, act as phagocytic scavenger cells that clear cellular 
debris from areas of injury or infection. This function has led some neuroscientists to 
view microglia as a subtype macrophage (30, 31). Initiation of microglial activation leads 
to a cascade of molecular mechanisms that induces the transformation of microglial 
morphology and physiology that facilitates the elimination of pathogens and the isolation 
of injured tissue (30, 32). This activational state in microglia is marked by the 
expression of a multitude of cell surface markers such as complement receptor 3 and 
toll-like receptor 4, which aids in phagocytosis and pathogen recognition (33, 34). 
Activated microglia, like their fellow phagocytic scavenger cells macrophages, sensitize 
and secrete a variety of signaling molecules including cytokines, neurotrophic factors 
and chemokines, which aid in combat against pathogens and isolation of damaged 
tissue. Additionally microglia, during activation, function as activators of adjacent 
astrocytes through the release of pro-inflammatory cytokines tumor necrosis factor-α 
(TNFα), interleukin-6 (IL-6), and interleukin-1β (IL-1β) (35-37).  These along with 
numerous other signal molecules, in addition to their abilities to facilitate the elimination 
pathogens and the isolation of injured tissue, allow microglia to direct CNS function and 
influencing human health and disease (30, 32, 35-37).  
 
B. Astrocytes: 
Astrocytes, the most abundant glial of all glial cells, were long believed to be 
only a supportive component of the CNS, and their reactive state viewed merely as a 
marker for CNS disease (25, 38). This view has greatly changed in the past few 
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decades with a deep interest being placed on the biological importance of astrocytes 
under normal and pathologic conditions (39). Active roles for astrocytes in numerous 
functions essential for proper and healthy activity of the CNS have been established, 
some of which are providing energy metabolites to neurons, enhancing neuronal 
survival under stressed conditions, modulating extracellular balance of ions, and 
synaptic transmission (18, 40-42). Insults to the CNS initiates a series of metabolic and 
morphological changes in astrocytes commonly referred known as reactive gliosis or 
astrogliosis (Figure1). The hallmark of this phenomenon is up regulation of glial fibrillary 
acidic protein (GFAP), which is often accompanied with cell hypertrophy and the 
release of both pro- or anti-inflammatory signaling molecules (43-47). Reactive 
astrocytes contribute to scar formation and neuronal death. Astrocytes, under certain 
circumstances, mediate dystrophic effects within the central nervous system and 
thereby contribute to a decline in neurological functions (48, 49). A multitude of 
intercellular and intra-cellular signaling pathways have been implicated to ignite the 
metamorphosis of astrocytes to the reactive state of astrogliosis as well as guide both 
their deleterious and beneficial actions in a context depended manor (50). However, the 
detailed molecular mechanisms that direct the phenomenon known as astrogliosis are 
incompletely characterized presenting a gap in our understanding of overall CNS 
pathology (50, 51). 
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Figure 1. Morphological changes in astrocytes occur during reactive gliosis or 
astrogliosis. A, The sections (lateral 2.00 mm) of mouse cerebral cortex with 
inactivated astrocytes (panel a) and activatived astrocytes (panel b) stained with anti-
GFAP antibody.  Some reactive astrocytes are indicated by white arrows.  B. Model of 
the functional and morphological changes that occur during reactive gliosis. 
 12
BI. Astrocyte Classifications:   
BI (i). Fibrous astrocytes:  
Neuroanatomists described astrocytes as contiguously present through the 
entire CNS. These contiguously organized cells have long been divided into two major 
classifications, fibrous and protoplasmic, based on cellular morphologies (52). Fibrous 
astrocytes of the white matter have many long unbranched processes with a much 
simpler morphology than protoplasmic astrocytes.  This simple morphology is indicative 
of fibrous astrocytes functions in metabolic support (53).  Analysis of the microstructure 
of fibrous astrocytes has revealed that the end-feet of their processes contact to nodes 
of Ranvier and like protoplasmic astrocytes they form gap junctions with the processes 
of adjacent astrocytes (54, 55).  
 
BI (ii). Protoplasmic astrocytes:  
The most abundant and dynamic glial cells, protoplasmic astrocytes, are highly 
polarized cells and found throughout the gray matter (52). Protoplasmic astrocytes have 
a number of stem branches from which a multitude of finely branched processes arise.  
These fine processes project to envelop vascular walls facilitating astrocytic regulation 
of neurovascular flow. Additionally the fine processes of protoplasmic astrocytes 
surround synapses thereby invoking and maintaining microregulation of the synaptic 
environment (53, 56, 57). This illustrates how the seemly subtle actions of astrocytes 
can cause dramatic affects in both health and disease states of the CNS. 
 
BII. Astrocyte Function in the Health CNS: 
BII (i). Astrocytes in CNS development: 
While astrocytes develop after the formation of neurons in a number of CNS 
areas, astrocytes have a variety of functions critical to development of the gray and 
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white matter in the human brain (58). This variety is illustrated in astrocytes creation of 
a molecular scaffolding that directs neuronal migration and axonal outgrowth during 
neural development (59). Additionally astrocytes promote synaptogenesis through the 
delivery of growth factors and molecular signals such as cholesterol that aid in synapse 
formation (60-62). In the white matter astrocytes form gap junctions composed of 
connexins with oligodendrocytes which facilitate intercellular ion flow critical for proper 
myelin development (63). These early actions further show critical and diverse functions 
carried out by astrocytes as early as CNS development.   
 
BII (ii). Astrocytes in the neural vascular: 
Astrocytes direct a ballet of bidirectional interplay with cerebral blood vessels 
and neurons which facilitates microregulation of CNS blood flow meditated by neural 
activity (64).  Consistent with this interplay is a synergistic relationship between the 
synaptic activity of glutamatergic neurons and vascular flow to the microenvironment. 
The uptake of glutamate by astrocytes in the synaptic cleft leads to the activation of 
glutamate receptors on astrocytes and the subsequent release of vascular modulators 
including nitric oxide, arachidonic acid and prostaglandins (65, 66). These synaptic 
mechanisms make astrocytes a vital connection between neuronal activity and CNS 
blood flow (67).   
 
BII (iii). Astrocytes in CNS homeostasis: 
The homeostatic maintenance of the cellular environment is critical for its 
function.  Processes grow out from astrocytes to engulf a neuron’s synaptic area.  This 
action allows astrocytes to conduct a symphony of homeostatic orchestration of fluid, 
ion and transmitter levels in the synaptic microenvironment (68, 69). Exploiting 
abundantly expressed aquaporin 4 water channel along the membranes of its endfeet 
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which interacts directly with microvessels, astrocytes modulate fluid homeostasis in the 
CNS (70, 71). Astrocytes execute additional regulatory maintenance of pH and ions that 
forges homeostasis of the CNS through the utilization of monocarboxylic acid 
transporters, vacuolar-type proton ATPase, bicarbonate transporters and Na+/H+ 
exchangers, embedded in their membranes (72). The uptake of neurotransmitters such 
as glutamate, gamma-aminobutyric acid, and glycine from the synaptic cleft by 
astrocytes is critical to healthy synaptic function (73, 74). Following this uptake, 
astrocytes metabolize the transmitters into their inactive forms, which are subsequently 
recycled back to the synapse for reuse or released into the extracellular space. This 
further illustrates the elegant way astrocytes govern effects over the intensities of neural 
communication (42, 75).  
 
BII (iv). Astrocytes in synaptic regulation: 
The synaptic modulation induced by the multidirectional interplay between 
astrocytes, neurons and the neural vascular niche extends beyond vascular regulation, 
homeostatic maintenance and synaptic formation. Astrocytes act to directly modulate 
signal transduction through the synthesis and secretion of synaptically active 
gliotransmitters such as glutamate, and gamma-aminobutyric acid (76, 77). Additionally 
astrocytes can generate and release signal molecules like the cytokine tumor necrosis 
alpha (TNF) to influence the uniform adjustments in the intensity of synaptic activity 
made as response to prolonged alterations in the neural electrical activity (78). The 
synthesis, metabolism and eventual release into the synaptic space of neuromodulatory 
steroids including testosterone, estradiol, progesterone and metabolites, represents 
another of the many mechanisms by which astrocytes manipulate synaptic activity. This 
utilization of metabolic activities shows how astrocytes mediate an additional level of 
sensitivity and neural modulation to system-wide changes (79).  
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BII (v). Astrocytes in metabolic regulation: 
Astrocytes as the primary source of glycogen in the CNS have dynamic 
interactions with neurons and the vascular system that make them important mediators 
of energy metabolism in the CNS (18, 80). This astrocyte-neuron interplay is illustrated 
by glutamatergic neurons at high neural activity eliciting lactate production and release 
from astrocytes in response in to a loss in function of phosphofructokinase and neuronal 
glycolysis (81).  Consistent with this view, activation of glutamate receptors in 
astrocytes induces astrocytic uptake of glucose from the vascular system and 
subsequent release of lactate (82). Astrocytes’ contribution of lactate for neuronal 
metabolic energy extends beyond the uptake of vascular glucose initiated by glutamate. 
During states of hypoglycemia and high neuronal activity, neural signal molecules such 
as noradrenaline, invoke glycogenolysis and lactate efflux (83, 84). These and other 
mechanisms illustrate the vast importance of astrocytes in normal CNS function and the 
potential grave effects if disruption of these astrocytic functions would have on the CNS 
and cognitive function (38, 42).   
 
BIII. Reactive Astrogliosis: 
With such a vast array functions for astrocytes it’s not surprising that reactive 
astrocytes or reactive astrogliosis have primary and secondary affects on the disease 
pathology of the CNS with direct and even grave implications on patient outcome (39, 
50, 85). Growing evidence suggests the phenomenon know as astrogliosis conducts 
both beneficial and deleterious affects on the CNS depending on the nature and degree 
of the insult. Despite decades of research and numerous pathological implications the 
fundamental questions about this phenomenon are just beginning to take shape (50). 
Answering even the most basic questions about astrogliosis has become difficult 
for even the best neurobiologists and neuroanatomists. Immense amount in vitro and in 
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vivo studies have suggested a definition for reactive astrogliosis. Reactive astrogliosis is 
a reaction to any affront to the CNS, characterized by an array of biological 
augmentations. These augmentations are directed with a scaled response indicative of 
the affront and the cellular environment in which it occurs, illustrated by signaling 
alterations, progressive cellular hypertrophy, and potential glial scar formation (50, 86, 
87). The both advantageous and disastrous affects of the phenomenon known as 
reactive astrogliosis are invoked through the multiplication of astrocyte function and 
subsequent secondary actions on the surrounding CNS environment (46, 88, 89). Thus 
determining the nature of this scaled response and the molecular factors that invoke 
these changes are critical to our understanding of the CNS and treatment of 
neurological pathologies.     
 
BIII (i). Resolvable reactive astrogliosis: 
Moderate or resolvable reactive astrogliosis, as the name implies, can revert to 
healthy tissue if the initiating affront is cleared. However the lasting effects and nature of 
the resolution of reactive astrogliosis have yet to be elucidated. This form of reactive 
astrogliosis can arise from mild non-penetrating and non-contusive trauma, at distal 
sites of severe trauma, and non-focalized infection (50). Resolvable reactive astrogliosis 
is marked with cellular hypertrophy and a hallmark increase in GFAP expression (50, 
90). This hallmark increase of GFAP expression creates the illusion of astrocytic 
proliferation in resolvable reactive astrogliosis. Staining for GFAP a cytoskeleton protein 
widely expressed in the cell bodies of many protoplasmic and fibrous astrocytes, can 
under estimate the total number of astrocytes in health CNS. Thus with this increase in 
GFAP expression in resolvable reactive astrogliosis comes increased appearance of 
astrocytes (91). Perhaps the most distinguishing feature of resolvable reactive 
astrogliosis from other forms of reactive astrogliosis is the conservation of the non-
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overlapping adjoining realms of dense networks of elegantly branched astrocytic 
processes, in face of cellular hypertrophy (92, 93). This conservatory act is thought to 
facilitate the resolution of reactive astrogliosis upon the clearance of the initiating 
affront.  That said, even the mechanistic process of this resolution and potentiating 
effects of the astrogliosis remain elusive (50).  
 
BIII (ii). Severe reactive astrogliosis: 
Under the assault of inflammatory effects and tissue damage from focalized 
infection, penetrating or contusive trauma, degenerative disease, autoimmunity and 
other major attacks to the CNS, astrocytes of the CNS give rise to severe reactive 
astrogliosis (94-96). Severe reactive astrogliosis is defined by high hypertrophic cell 
bodies and processes of proliferating astrocytes that have expanded beyond the 
boundaries of individual astrocytes, blending with other astrocytes to create a blur of 
astrocytes with strong GFAP expression (92, 50). While knowledge of the mechanisms 
that induce this proliferation are limited, it is a striking feature demonstrated in CNS 
dysfunction when considering that the vast majority of astrocytes in healthy CNS are 
long-living post-mitotic cells (97, 98). This striking and poorly understood process 
exacerbates the blurring of astrocytic boundaries which are believed to invoke many of 
the lasting effects seen in severe reactive astrogliosis.  This underpins the importance 
of understanding the molecular mechanism of severe reactive astrogliosis (50). 
The loss of astrocytic boundaries in addition to alteration of the cellular 
architecture of the surrounding tissue, at excessive levels of astrocytic activation guides 
glial scar formation (94, 99, 100). Inflammatory cytokines such as IL-6 are believed to 
stimulate proliferation in reactive astrocytes through the up regulation of epidermal 
growth factor expression (101). These proliferating astrocytes intermingle with other 
glial cells, fibroblasts and other cells of the surrounding CNS to form glial scars (100, 
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102). Once formed these glial scars can serve as neuroprotective barriers that isolate 
infectious pathogens, inflammatory cells and other deleterious agents within the 
damaged or injected tissue (94, 95, 99). Glial scarring, while beneficial, is far from free 
of adverse affects illustrated in its ability to hinder axonal regeneration (103). 
Importantly unlike resolvable reactive astrogliosis the effects of severe astrogliosis are 
long lasting therefore understanding these functional affects that can influence clinical 
outcome is critical to treatment of CNS dysfunction (50). 
 
BIII (iii). Beneficial nature of reactive astrogliosis: 
Reactive astrogliosis has long been viewed as purely deleterious in nature, 
although this view has transformed over the last twenty years to one of dual nature.  It is 
now known that astrogliosis conducts an array of advantageous functions, many of 
which are adaptations of astrocytic function during non-pathological conditions (50).  
This adaptive metamorphosis is demonstrated in the astrocytes’ ability to regulate 
extracellular glutamate levels, and the exploitation of this trait to take up excess 
glutamate during periods of pathologically generated excitotoxic levels of glutamate 
(104, 105).  Furthermore the dynamic interplay between astrocytes with the vascular 
system and the homeostasis of the neural extracellular microenvironment allows them 
to reduce edema follow trauma or stroke as well reduce seizure intensity through ion 
modulation (71, 106). Astrocytic regulation of the extracellular microenvironment yields 
additional protective effects through the uptake and degradation of toxic ammonium and 
amyloid peptides (107, 108). This further demonstrates the extraordinary way 
astrocytes transform within the framework of their dynamic and poorly understood 
molecular machinery to perform functions that can shape the outcome of human health 
during pathological states.      
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Astrocytes can have beneficial functions during reactive astrogliosis apart from 
their actions during non-pathological states. This gain is visible in astrocytic secretion 
and production of molecular protectors in response to an assault.  This is demonstrated 
in the release and production of the master antioxidant glutathione in response to toxic 
levels of Nitric oxide (109). These and other neuroprotective actions of reactive 
astrogliosis have altered our approach to CNS pathology.  Although a clear mechanistic 
understanding of reactive astrogliosis inductions of these actions over deleterious ones 
remain to be elucidated (50).  
 
BIII (iv). Deleterious nature of reactive astrogliosis: 
While the view of reactive astrogliosis as purely detrimental has changed, it is 
equally important to remember that reactive astrogliosis is far from purely beneficial.  
For instance reactive astrogliosis can induce disruption in any a number of essential 
functions astrocytes carry out, including regulation of neurovascular flow, synaptic 
homeostasis, and energy metabolism, all which could be disastrous to CNS (42). This 
deleterious outcome is illustrated in the excitotoxic neurodegeneration occurring 
through the disruption of neurotransmitter uptake (104, 110).  This further demonstrates 
the essential roles inactive astrocytes play in the biology of the CNS, and the grave 
effects augmentation and manipulation of astrocyte functions can have on clinical 
outcome. These grave effects create a genuine need for understanding the molecular 
processes of reactive astrogliosis.    
Just as existing functions can be augmented and new ones gained to yield 
beneficial effects, they can be altered and gained with disastrous outcomes during 
reactive astrogliosis. Many of these context-dependent detrimental functions are a 
reversal of the beneficial effects that can be induced by reactive astrogliosis one 
example is release of glutamate at potentially toxic levels, rather then uptake and break 
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down of excitotoxic glutamate (104, 111). This reversal of roles is further exemplified in 
the augmentation of water channel aquaporin-4 which invokes excessive edema 
following a stroke (71, 112). This being said the exact nature of reactive astrogliosis 
during ischemic disease remains unclear (113). Epilepsy, or more broadly stated 
seizure disorders are not free of this dual nature of reactive astrogliosis which varies 
with the intensity of the seizures.  Reactive astrogliosis invokes its deleterious nature 
through the augmentation of extracellular levels of potassium in favor of neuronal 
hyperexcitability and epileptogenesis (114, 115). Additionally, astrocytes can gain the 
ability to produce and secrete a multitude of deleterious agents not readily seen in 
health, CNS during reactive astrogliosis such as inflammatory cytokines and noxious 
levels reactive oxygen species (116-118). During reactive astrogliosis these noxious 
agents have been shown to influence the development of neuropathology in a context-
dependent manner as in the case in the development of neuropathic pain (119). These 
clinic implications highlights the grave importance of better understanding the induction 
mechanisms of astrocyte activation and the regulatory actions that take place during 
this state which could be of value in the treatment of pathologic conditions in the CNS.   
 
BIII (v). Triggering and signaling events of reactive astrogliosis: 
Reflective of their ability to respond to any affront to the CNS, astrocytes can be 
activated by a multitude of agents, arising from an array of sources some of which are 
other cells of the CNS, vascular system and immune cells (50). Microglia and other 
immune cells induce reactive astrogliosis through the induced expression of cytokines 
such as IL-6, IL-1 and TNF exemplify this process (120). Further, immune sensitivity 
can be invoked through the use of Toll-like receptors on astrocytes (121). Indicative of 
astrogliosis reactivity to stress, it is not surprising that a multitude of signaling molecules 
released during states of physiological stress and neurodegeneration including reactive 
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oxygen species, beta amyloid, and noxious levels of ammonium, can induce reactive 
astrogliosis (122 -124). Additionally astrocytes the have ability to respond to abnormal 
neural activity with astrogliosis induction in response to toxic levels of neurotransmitters 
like glutamate (125). While a vast number of inducers of reactive astrogliosis have been 
identified, the detailed molecular mechanisms of astrocyte activation are just starting to 
take shape.  
Even with our limited understanding of astrocyte activation, a number of 
signaling pathways have been implicated in a gene expression profile associated with 
functional features of reactive astrogliosis (50). Recent studies have suggested that 
endothelin-1 (ET-1) a key mediator of vascular tone and subsequent activation of the c-
Jun/JNK pathway is involved in the poorly understood mechanism of astrocyte 
proliferation during brain injury induced reactive astrogliosis (126, 127). Signal 
transducer and activator of transcription 3 (STAT3) was implicated by a conditional 
deletion study to have a role in astrocyte hypertrophy following spinal cord injury (128). 
STAT3 function does not end there. STAT3 and Ephrin type-B receptor 2 are implicated 
in glial scar formation after spinal cord injury (128, 129). STAT3 along with suppressor 
of cytokine signaling 1 and 3 augmentation of cytokines and chemokines have been 
suggested to have a mechanistic role in the anti-inflammatory effects induced by 
activated astrocytes (128, 130).  STAT3 and nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-B) influence the hallmark expression of structural proteins 
GFAP, vimentin, and nestin during astrocyte activation following spinal cord injury (128, 
131). Additionally NF-B is a regulator of immune and inflammatory aspects of 
astrocyte activation (131). These pathways with an array of others give us some 
understanding of the mechanisms behind reactive astrogliosis. Nevertheless, these 
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mechanisms remain poorly understood and respect a gap in our understanding of CNS 
pathology thereby limiting effective treatment of neurologic disease (50).  
 
C. NF- B Involvement in Astrogliosis: 
NF-B is a transcription factor found in the cytoplasm and nucleus of most cells 
including astrocytes, with a number of complex roles in both beneficial and deleterious 
mechanisms during different pathology states in the CNS (132-134).  In mammals, the 
NF-B family is composed of five members: NF-B1 (p105/p50), NF-B2 (p100/p52), 
RelA (p65), RelB, and c-Rel. These further come together to create at least two major 
NF-B pathways. The canonical or classical NF-κB pathway is believed to be the 
primary NF-κB pathway in astrocyte activation (132, 134).  The activation of this 
pathway can begin with stimulation from a multitude of signal molecules such as TNF, 
IL-1, direct pathogen signaling through a Toll-like receptor, and oxygen-free radicals. 
Activation of a stimulatory cascade invoked by these signaling events leads to the 
activation of a complex of proteins known as IκB kinase (IKK).  IKK phosphorylates 
serine 32 and serine 36 on IκB which is bound to the Rel-homology domains of p50 
and p65. This binding conceals their nuclear localization signal (NLS), thus acting as in 
inhibitor of transcriptional activity.  Phosphorylation tags IκB for ubiquitination at 
positions Lysine 21 and Lysine 22 and subsequent degradation by the 26S proteasome. 
This degradation frees the NLS of p50 and p65, to facilitate their nuclear localization. 
Once in the nucleus they form heterodimers with each other and p65 forms 
homodimers. The homodimers and heterodimers associate with coactivator proteins 
before binding to response elements in the DNA and inducing gene transcriptional 
affects (132, 135). This powerful and dynamic transcriptional activity allows NF-B to 
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augment the expression of a vast number of genes, which in turn gives it regulatory 
actions in the induction of activational states of astrocytes (132, 50). 
It is not surprising with NF-B ability to influence over 150 genes including cell 
cycle regulators, chemokines, cytokines, and neurotrophic factors that it has both 
protective and deleterious implications in CNS assaults (133, 136, 137). One such gene 
suggested by recent studies to have involvement in astrocyte activation is the cyclin-
dependent kinase inhibitors p21Cip1 (138-140). Studies using p21Cip1 deficient astrocytes 
have suggested that p21Cip1 expression can increase NF-B activity in astrocytes (140, 
141). Another study in epithelial cells shows an association with p21Cip1 over expression 
with NF-B activation.  There data were strengthened by a decrease in NF-B induced 
growth inhibition in p21Cip1-/- epithelial cells (142). These studies allude to a possible 
bidirectional mechanism where p21Cip1 and NF-B activity is interconnected.  
NF-B has dual effects during pathological states in the CNS with beneficial and 
deleterious actions. This dichotomy is illustrated in the protective effects on neurons 
through the release of neurotrophic factors during reactive astrogliosis while inducing 
the expression of inflammatory cytokines and genes potential inducers of reactive 
astrogliosis such as p21Cip1 (50, 136, 140).  The protective nature of NF-B was 
described in a recent study that suggested it stimulates of the production and secretion 
of neurotrophins by astrocytes (143). In another study using transgenic mice expressing 
a dominant negative (dn) form of the inhibitor of Bdriven by GFAP promoter the loss 
of NF-B activity following spinal cord injury resulted in decreased GFAP expression 
and glial scaring (131). This decrease was accompanied by a reduction in astrocytic 
production of proinflammatory chemokines and cytokines, such as CXCL10, CCL2 
(131). Additionally in a different study using a similar transgenic model astrocytic NF-B 
activity was shown to enhance the pathogenesis of experimental autoimmune 
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encephalomyelitis through the induction of increased cytokine and chemokine response 
from glial cells (133). These and other studies suggest astrocytic NF-B plays a role in 
reactive astrogliosis and neuropathology (50).  

D.  Androgen Receptor (AR) Involvement in Astrogliosis: 
 
Present in a vast array of cells including astrocytes, AR is a nuclear receptor 
that plays a critical role in the regulation of gene expression in reproduction, 
development, and metabolism (143-147). AR controls gene expression by acting as a 
ligand-activated transcription factor of target genes mediated by androgens. Upon 
binding of androgens to AR there is a release of heat shock proteins, receptor 
dimerization, and AR binding on androgen-response elements (ARE) located within AR-
target genes.  During its activation by androgens, AR physically interacts with a medley 
of cofactors or coregulators that modulate AR transactivation during different 
physiologic states (148-158). One such physiologic state is astrogliosis (159-162). 
However the molecular mechanisms underlying this regulatory control remain unclear.  
The brain is an important target for androgen (163). Acting on the brain, 
androgen regulates reproduction and sexual and aggressive behaviors (164, 165).  
Androgens also prevent neuronal death in neurodegeneration, and decreased androgen 
levels in plasma increase the risk of development of neurodegenerative diseases in 
humans (166).  During brain development androgen affects, the differentiation of GFAP-
positive astrocytes (167-169).  In the adult brain, androgens regulate the expression of 
GFAP in the hippocampus (170). In addition, androgens act as a negative regulator of 
reactive astrogliosis, illustrated by a reduction GFAP in reactive astrocytes in brains 
subject to injury and androgen treatment (159-162). These studies suggest that 
androgens and AR may protect neurons of the CNS through inhibiting astrogliosis 
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(171). This molecular mechanism of androgen action has yet to be elucidated. The roles 
of the androgen receptor and its associated proteins represent a critical gap in our 
understanding of the direct role of astrocytes in all pathologic and non pathologic states 
of the CNS.  
 
E. P44/WDR77: 
P44/WDR77 is an AR cofactor that was identified by co-immunoprecipitation 
with AR from prostate cancer cell line (172). The human p44/WDR77 protein contains 
342 amino acid residues and 7 putative WD-40 repeats which facilitate protein–protein 
interactions (172, 173). Northern blot analysis showed that p44/WDR77 mRNA is 
expressed in multiple human tissues (172). Prior studies have illustrated that 
P44/WDR77 is a component of the methylsome complex with protein arginine methyl 
transferase 5 (PRMT5) (172, 174). PRMT5 is a member of the protein arginine 
methyltransferase family of coactivators providing support for a role for p44/WDR77 in 
transcriptional activation (175). Additionally p44/WDR77 shares its protein sequence 
with the WD45 subunit of the survival motor neuron (SMN) complex, here P44/WDR77 
aids in the assembly of the small nuclear ribonucleoprotein (snRNP) complex (174, 176, 
177). Interestingly the SMN is only active in the cytoplasm suggesting p44/WDR77 has 
distinct cytoplasmic and nuclear function (178). This with its role as AR cofactor 
provides evidence that p44/WDR77 could be involved in a multitude of dynamic 
mechanisms in various cells at varying differential states.   
As an AR cofactor p44/WDR77 (Figure 2) selectively regulates a set of AR-
target genes including p21Cip1 in the prostate gland and prostate cancer (152, 172, 179).  
In normal prostate epithelial cells p44/WDR77 localizes to the nucleus, whereas in 
prostatic intraepithelial neoplasia and prostate cancer p44/WDR77 localizes to the 
cytoplasm (179).  Experimentally induced nuclear localization of p44/WDR77 in prostate 
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cancer cells inhibited cell growth via G1 cell cycle arrest (179, 180). In addition, the 
p44/WDR77-null prostate epithelial cells were less differentiated relative to those in the 
wild-type litermates (181). Thus, the nuclear p44/WDR77 is required for growth 
inhibition and full differentiation of prostate epithelial cells through selectively 
modulating expression of a set of AR-target genes. The p44/WDR77 nuclear export 
might be an essential step that relieves the p44-mediated growth inhibition and resumes 
proliferation, which is required for prostate tumorigenesis.  However, the role of 
p44/WDR77 in other cell types like astrocytes remains unexplored. 
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Figure 2. P44/WDR77 functions as a cofactor for androgen receptor. Model that 
illustrates p44/WDR77 ability to physically associate with AR and regulate AR-driven 
transcriptional activity. 
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Chapter II.  Materials and Methods 
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A. Animals and brain dissection 
The homogenous mice (p44/WDR77loxP/loxP) and a cross between p44/WDR77loxP/loxP 
(WT) and PRR2Bi-Cre mice to generate p44/WDR77loxP/loxP;Cre (MT) mice were 
described previously (181, 182). In another line of experiments ARR2PPbi-Cre 
transgenic mouse, were crossed with the mouse line B6;129-Gt(37)26tm1Sor mouse (The 
Jackson Laboratory, #003309) (183).  All mice are on a C57BL genetic background and 
were handled in accordance with the guidelines published in the NIH Guide for the Care 
and Use of Laboratory Animals. The Institutional Animal Use and Care Committee at 
MD Anderson Cancer Center approved experimental procedures.  For genotyping, the 
genomic DNA isolated from mouse-tails was subjected to the polymerase chain reaction 
(PCR) analysis with 5’GTACCGGTCTGGTGAGCCGAGATC3’ and 
5’CAGGACGCCAGGTATGGCCGAGGAG3’. Organs were dissected from mice at the 
age of two months and weighted using an analytic balance. Mice were identified by 
PCR on tail snips, as previously described (179). Liter mate of different p44/WDR77 
genotypes were housed together and fed freely with standard mouse chow over their 
lifespan in a pathogen-free environment. Mice exhibiting extreme morbidity were 
sacrificed.   
Mice were anesthetized until they no longer displayed a withdrawal reflex in the hind 
limbs according to procedures approved by the MDACC Animal Research Committee.  
The animals were intracardially perfused with chilled PBS for approximately two 
minutes and then with Fresh Formalde (Fisher) for 15 minutes. The animals were 
decapitated, soft tissue removed, and the skulls were post-fixed in Fresh Formaldehyde 
for 16 hours at 4oC. The brains were removed from post-fixed skulls and sliced into 1 
mm sectional pieces. The sliced tissues were put into cassettes, washed with different 
concentrations of ethanol, and then embedded in paraffin. Sections (4m) were cut and 
 30
mounted on Super-frost Plus adhesion slides (Fisher) for hematoxylin and eosin (H&E) 
and immunohistochemical staining.   
Dorsal skin sections and cross sections of spleens and skin were fixed in Fresh 
Formalde for 16 hours at 4oC, embedded in paraffin, and stained with haematoxylin and 
eosin.  The heights of the cross sections of spleen and skin were measured under a 
light microscope.  The means of heights from 5 spleens and skins were presented. 
 
B. Isolation and culture of mouse astrocytes 
A tissue culture system of primary astrocytes was derived from newborn mouse 
cerebra cortex (184). The newborn mouse pups (n=8-10) were sacrificed in a CO2 
chamber.  The brains were dissected from mouse skull and transferred to a 60mm Petri 
dish with ice-cold Hank's Balanced Salt Solution (HBSS). The brainstems, olfactory 
bulbs and cerebellums were cut off and the two hemispheres were separated.  The 
hemispheres were cleaned out (i.e. remove the hippocampus, basal nuclei, the 
meninges, and blood vessels) leaving the neocortex. The hemispheres were minced 
with the small iris scissors and digested with 2ml of collagenase (87.5U/ml) 
(Worthington Biochemical Corp) and 40μg/ml deoxyribonuclease (Sigma-Aldrich) in low 
glucose Dulbecco's modified essential media (DMEM) for 30 minutes at 37°C. After 
centrifugation, cell pellet was dispersed and resuspended in low glucose DMEM 
supplemented with 10% Bovine Calf Serum (BCS), NaHCO3 500mg/L, and 1% 
Penicillin-Streptomycin.  The cells from each brain was filtered through a 50μm sterile 
mesh and placed in culture flasks that had been coated with 5μg/ml mouse laminin 
(Sigma-Aldrich).  When the astrocytes were grown confluent (10-14 days) they were 
ready to be shaken for overnight at 37oC (to remove the microglial, oligodendrocytes 
and neurons) and then 1:4 split. Astrocytes contain characteristic intermediate filaments 
 31
(GFAP), which could be readily identified in the cultured cells. The GFAP-positive cells 
were more than 95% in the cultured cell population.   
A confluent plate of astrocytes were harvested and fixed in 4% paraformaldhyde 
for 20 minutes. The fixed astrocytes were embedded in 0.9% low melting agarose 
(Sigma-Aldrich). The agarose pellet was embedded in paraffin and sections (4m) were 
cut and mounted on Super-frost Plus adhesion slides (Fisher) for immunohistochemistry 
analysis.  
 
C. Immortalization of astrocytes 
The Phoenix A packaging cell line was maintained in DMEM supplemented with 10% 
FBS and transfected with pLXSP:HPV16-E6/E7 using lipofectamine 2000 (Invitrogen) 
(185). The culture medium was replaced with the fresh low glucose DMEM 
supplemented with 10% BCS 48 hours post transfection. The virus was collected 12hr 
later and used to infect the primary astrocytes from WT (p44/WDR77loxP/loxP) MT 
(p44/WDR77loxp/loxP;Cre), and p44/WDR77+/+ mice in the presence of 8g/ml polybrene 
(Sigma-Aldrich). Two days after infection, the astrocytes were 1:4 split and selected 
with 1μg/ml puromycin for three weeks. Total of 8 WT, 20 MT, 8 p44/WDR77+/+ 
astrocyte colonies were picked and expanded. 
 
D. The Cre-mediated deletion of the p44 gene in mouse astrocytes  
Immortalized WT astrocytes (2.5 x 105) were plated on 100mm plate in low glucose 
DMEM with 10% BCS and 18 hours later, infected with 1.25 x 109 virus particles of 
adenovirus Ad5-CMV-GFP (Baylor College of Medicine) or Ad5-CMV-Cer-GFP (Baylor 
College of Medicine). Fresh media was added three days post infection. GFP 
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expression in the infected astrocytes was examined under a fluorescent microscope 
and a 100% infection efficiency was achieved (Figure 16). Two adenoviruses used were 
replication-deficient, and transcription of GFP and Cre cDNAs was under the control of 
a CMV promoter. Deletion of the p44/WDR77 gene was confirmed using PCR and 
p44/WDR77 expression was analyzed by immunostaining and Western blot analysis 
with anti-p44/WDR77 antibody. 
 
E. Northern blot assay 
Northern blot analysis was performed as previously described (186).  The mRNAs were 
isolated from whole brains of WT (n=5) or MT (n=5) male mice at the age of two months 
and transferred to a Hybond N+ membrane (Amersham Biosciences). The membrane 
was hybridized with cDNA probes of p44/WDR77 and -actin genes. 
 
F. BrdU labeling 
Mice were injected by intraperitoneal with Bromodeoxyuridine (BrdU) 0.1mg per gram of 
body weight (Sigma-Aldrich) and skin and spleen were dissected 24 hours later, fixed in 
Fresh Formalde for 16 hours at 4oC, and embedded in paraffin. Sections (4m) were 
cut and mounted on Super-frost Plus adhesion slide for immunostaining the BrdU-
labeled cells employing a monoclonal anti-BrdU antibody (BD Pharmingen™). The 
labeled cells were calculated from three fields of each slide. Three sections from each 
organ were analyzed to obtain the mean of BrdU positive epithelial cells. The means of 
the proliferating cells from 5 mice were presented. 
Primary WT and MT astrocytes (1 x 106) were plated on 100mm plate in low 
glucose DMEM with 10% BCS and 18 hours later, the cell were incubated at 37oC with 
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culture medium containing 10M BrdU.  Four hours later the astrocytes were harvested 
and fixed in 4% paraformaldhyde for 20 minutes. The fixed astrocytes were embedded 
in 0.9% low melting agarose. The agarose pellet was embedded in paraffin and 
sections (4m) were cut and mounted on Super-frost Plus adhesion slides for 
immunohistochemistry analysis.  
 
G. -Galactosidase (-gal) Staining 
B6;129-Gt(37)26tm1Sor mouse (The Jackson Laboratory, #003309) were crossed with the 
ARR2PPbi-Cre transgenic mouse. Animals [B6;129-Gt(ROSA)26Sor/J (negative 
control)] and B6;129-Gt(ROSA)26Sor/J-ARR2PPbi-Cre (F1 heterozygous mice) at two 
months of age were anaesthetized and perfused with 4% paraformaldehyde. The brains 
were removed and fixed in 4% paraformaldehyde for 1 hour and sliced sagittal at 0.00 
mm plane. The brain slices were fixed with 4% paraformaldehyde overnight and 
processed for paraffin embedding.  The whole brains and tissue section were fixed for 
10 minutes with 0.5% Gluteraldehyde in PBS at 4°C and washed three timed with PBS.  
Specimens were then placed in PBS containing 10 mmol/L K3Fe(CN)6 and 10 mmol/L 
K4Fe(CN)6 along with the -gal substrate [5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-gal)] (1 mg/mL).  Specimens were incubated at 37°C for eight 
hours, washed well in tap water, and counterstained with Hematoxylin Solution (Sigma).  
 
H. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
Animals (n=5, WT and n=5, MT) at the age of three months were anaesthetized and 
perfused with 4% paraformaldehyde. The brains are removed and fixed in 4% 
paraformaldehyde for 1 hour and sliced sagittal at 0.00 (B3), 1.00 (B4), 2.00(B2 and 
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B4), and 3.00 (B1 and B6) mm planes. The brain slices were fixed with 4% 
paraformaldehyde overnight and processed for paraffin embedding. Blocks will be 
sectioned to obtain continuous specimens (4M each) placed on glass slide. Tissue 
sections deparaffinized followed the application of 40g/ml proteinase K (Sigma-
Aldrich). The sections were subject to a TUNEL assay utilizing the in situ cell death 
detection kit (Promega) according to the manufacturer’s instructions. TUNEL-positive 
cells and total cells determined using Hoechst staining (Invitrogen) from each section of 
WT and MT brains were accounted. The percentage apoptotic cells were calculated.  
Three sections (500M apart) from each brain were analyzed. The means of 
percentage apoptotic cells from 5 brains are presented. 
 
I. Microscopic observations of living cells  
Living immortalized WT and MT astrocytes were examined with white or green (to 
observe GFP) light under an Olympus IX71 microscope (Olympus Corp.) and a digital 
camera (Retiga 1300) interfaced to a computer with PCI software.  
 
J. Immunohistochemistry 
 Immortalized WT and MT astrocytes (3 x 104) were plated to 4-well chamber 
slides (Fisher) in low glucose DMEM with 10% BCS and 18 hours later, they were 
washed twice with PBS and fixed with cold (-20oC) methanol (Sigma-Aldrich).  The cells 
were blocked with 4% fish gel and primary antibodies were applied to the astrocytes 
sections and incubated overnight at 4oC. After washing with PBS immunofluorescent 
secondary antibodies were applied. The fluorescent signals were observed under a 
cofocal microscope.  The primary antibodies are omitted in negative controls. 
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 Tissue sections deparaffinized and subject to antigen retrieval. Tissue sections 
were blocked with 3% fish gel and primary antibodies were applied to the tissue 
sections and incubated overnight. A streptavidin-biotin peroxidase detection system 
was used according to the manufacturer’s instructions (DAKO). For double 
immunofluorescent staining, secondary antibodies were applied as described in Table 
1. The fluorescent signals were observed under a cofocal microscope with a green (to 
detect the p44/WDR77 protein) or red (to detect GFAP protein) filter. The primary 
antibodies are omitted in negative controls. 
 
 36
Table 2: Antibodies used in Immunohistochemistry 
 
Primary 
Antibodies 
Company Dilution Secondary 
Antibodies 
Dilution 
antigen-purified 
p44/WDR77 
described previously 
(172, 187) 
1:200 Alexa 488 
anti-rabbit IgG 
1:1000 
Fluorescent 
GFAP 
Neuromics 
(CH22102) 
1:1000 594 labeled 
anti-chicken IgG 
1:1000 
NEUronal Nuclei 
(NeuN) 
Chemicon 
(MAB377) 
1:500 594 labeled 
anti-chicken IgG 
1:1000 
class III β-tubulin 
(Tuj1) 
Neuromics 
(CH23005) 
1:400 594 labeled 
anti-chicken IgG 
1:1000 
p65 
 
Santa Cruz Biotechnology 
(sc-8008) 
1:1000 Alexa 594 
anti-mouse IgG 
1:1000 
Non fluorescent 
GFAP 
DAKO 
(Z0334) 
1:1000 Peroxidase labeled 
anti-rabbit IgG 
1:300 
BrdU 
 
Beckton Dickinson 
(347580) 
1:200 Peroxidase labeled 
anti-rabbit IgG 
1:300 
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K. Western blot analysis 
The mouse whole brain was homogenized in 0.5ml passive lysis buffer (Promega) using 
a dunce. Confluent 100mm plates of astrocytes were collected and lysed in 50l 
passive lysis buffer (Promega). After centrifugation at 12,000 rpm, 4oC for 12 minutes, 
the supernants were collected and protein concentrations were measured by the 
Bradford Reagent (Bio-Rad) with BSA as the standard. Ten micrograms of protein 
extracts were loaded on 12% sodium dodecyl sulfate (SDS) polyacrylamide gel and 
subject to electroporation at 175V for one hour. The proteins were transferred to 
0.45m polyvinylidene fluoride (PVDF) membrane (Millipore) using a Semi-Dry Transfer 
System (Bio-Rad Laboratories) at 6V overnight. The membranes were rinsed in 100% 
methanol (Sigma-Aldrich) and block for 1 hour in 3% nonfat dry milk in TBST (20 mM 
Tris-HCl, pH 7.6; 150 mM NaCl; and 0.1% Tween 20). The blots were subject to a two 
hour incubation with primary antibodies (Table 2) in 3% nonfat dry milk in TBST. After 
washing with TBST the blot were subjected to 1.5 hours incubation with secondary 
antibodies (Table 2) in 2% BSA in TBST. The blots were developed utilizing 
chemiluminescence kit (Amersham Biosciences). 
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Table 2: Antibodies used in Westernblots 
 
Primary 
Antibodies 
Company Dilution Secondary 
Antibodies 
Dilution 
p44/WDR77 described previously 
(172, 187) 
1:5000 Peroxidase linked 
anti-rabbit Ig 
1:5000 
p65 
 
Santa Cruz Biotechnology 
(sc-8008) 
1:1000 Peroxidase linked 
anti-mouse Ig 
1:5000 
GFAP DAKO 
(Z0334) 
1:1000 Peroxidase linked 
anti-rabbit Ig 
1:5000 
-Actin Sigma-Aldrich 
(029K4838) 
1:2000 Peroxidase linked 
anti-rabbit Ig 
1:5000 
p21Cip1 
 
Santa Cruz Biotechnology 
(sc-6246) 
1:1000 Peroxidase linked 
anti-rabbit Ig 
1:5000 
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L. Cell growth assay 
Immortalized WT and MT astrocytes (1 x 104) were plated in each well of 24-well plates 
in low glucose DMEM with 10% BCS and supplements. Cells will be counted every day 
with a hematocytometer. 
 
M. Fluorescence activated cell sorter (FACS) analysis 
Astrocytes were collected 14 days after adenovirus infection, washed with ice-cold 
phosphate-buffered saline (PBS), and then fixed in 70% ethanol at 4oC for 12 hours.  
After fixation, astrocytes were washed twice with PBS and incubated in PBS containing 
50g/ml propidium (PI) (Sigma-Aldrich), 20g/ml RNase A (Sigma-Aldrich), 0.1% 
Tween 20 (Sigma-Aldrich) for 20 minutes.  FACScan flow cytometry (Becton Dickinson) 
was used to measure the propidium–DNA complex. Cells in the sub-G1 population were 
identified as apoptotic. 
 
N. Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) 
 
Total RNAs were isolated from immortalized WT and MT astrocytes and from 
whole brain tissues using TRIzol regent (Invitrogen).  cDNAs were generated from the 
total RNAs using the Reaction Ready First Strand cDNA Synthesis Kit (Supper-Array 
Bioscience Corp).  The cDNA were subjected to PCR amplification for 40 cycles (30sec 
at 94°C; 20sec at 55°C; and 30s at 72°C) utilizing a mixture of RT2 real-time SyBRgreen 
PCR master mix and primers specific to mouse -actin (PPM02945A) or p21Cip1 
(PPMO2910A) purchased from SupperArray Bioscience Corp with the SmartCycler II 
(Cepheid). The expression levels of the samples were normalized to their -actin levels.  
Quantification and data analysis was generated with the aid of the SmartCycler 
Software (Cepheid; version 2.0C). 
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O. ShRNA knockdown 
Mouse p21Cip1 and p65 shRNA constructs and lentivirus production were 
performed by the Cloning Core Facility at Department of Cancer Biology in MD 
Anderson Cancer Center, using pLVTHM (addgene) vector. The target sequences used 
for the nontargeting control and mouse p21Cip1 and p65 are 
TTCTCCGAACGTGTCACGT, TTAGGACTCAACCGTAATA and 
GAGTTTCAGCAGCTCCTGAAC, respectively. Immortalized WT astrocytes (2 x 104) 
were plated in each well of 6-well plates in low glucose DMEM with 10% BCS and 
supplements. Twenty-four hours later, the astrocytes were infected with lentivirus in the 
four groups as follows, (i) non-targeting control virus; (ii) p21Cip1 shRNA-expressing 
virus; (iii) p65 shRNA-expressing virus; (iv) p21Cip1shRNA-expressing virus plus p65 
shRNA-expressing virus. GFP expression was examined for the infected astrocytes 
under a fluorescent microscope. This illustrated an 80% infection efficiency. Four days 
later, the virus was removed and the cells were split for experiments.   
 
P. Exogenous expression of p21Cip1 and p65 
Human p21Cip1 and p65 cDNA were subcloned into a lentiviral expression 
construct OG2 (clonetech) with a CMV promotor. Lentivirus production was performed 
by the Cloning Core Facility at Department of Cancer Biology in MD Anderson Cancer 
Center. Immortalized WT astrocytes (2 x 104) were plated in each well of 6-well plates in 
low glucose DMEM with 10% BCS and supplements. Twenty-four hours later, the 
astrocytes were infected with lentivirus in the four groups as follows, (i) control virus; (ii) 
p21Cip1-expressing virus;(iii) p65-expressing virus; (iv) p21Cip1-expressing virus plus p65-
expressing virus.  The virus was removed 4 days post infection and the cells were split 
for experiments.  
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Q. Quantification and statistical analysis 
The positive cells were counted in three fields of brain regions (three randomly selected 
non-overlapping 20X fields). Three brain sections (126-mm apart) for each brain block 
(plane) were counted. Cell counts were thus performed in the same volume of WT 
control and MT brains. To avoid double counting of the same cells, cell counting was 
done in brain sections 126 mm apart, which should be larger than most of brain cell 
diameters. Cell counts were carried out without knowledge of the genotype of mice. 
Data were analyzed by unpaired Student’s t-test. In cell counting experiments, the 
average value of the same counting on three microscopic fields of three brain sections 
from each brain block (plane) was used for statistical analysis. Differences between 
experimental groups were considered significant at P<0.05.  All values represent mean 
± S.E.M.  
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Chapter III: Preliminary Data 
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A. Loss of the p44/WDR77 gene decreased the mouse life span.   
 
AI. Rationale: 
AR controls the expression of a vast array of gene involved in reproduction, 
development, and metabolism (143-147). These regulatory actions are modulated by 
various cofactors or coregulators which physically interact with AR after ligand 
activation (148-158). One such cofactor is p44/WDR77 which was identified by co- 
immunoprecipitation with AR from a prostate cancer cell line (172). Previous studies 
indicate that p44/WDR77 directs critical functions in prostate tumorigenesis by affecting 
a subset of AR-target genes in prostate cancer (179, 180). Prostate-specific deletion of 
the p44/WDR77 gene will provide a better understanding on how p44/WDR77 control 
growth and differentiation of prostate epithelial cells (188). 
 
AII. Experimental Design: 
To achieve a prostate-specific deletion of the p44/WDR77 gene, we crossed WT 
(p44loxP/loxP) mice to the ARR2PPbi-Cre transgenic line (189), in which the Cre 
recombinase is expressed under the control of a modified prostate-specific probasin 
promoter. The promoter ARR2PPbi is a composite of the rat probasin promoter with two 
androgen responsive elements (ARE) (190). The probasin promoter has been shown to 
target gene expression to the epithelial cells of the prostate in transgenic mice (191).  
Studies utilizing ARR2PPbi-Cre mice indicate that the Cre recombinase is highly 
expressed in every lobe of mouse prostate (192).  
The mortality of fifty WT and forty-one MT mice was observed over the course of 
300 days postnatal. Mice exhibiting extreme morbidity were sacrificed, and their 
pathology was examined by a veterinary pathologist at MD Anderson Cancer Center. 
WT and MT mice were weighed using an analytic balance at 21, 30, 60, 90, and 120 
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days postnatal to determine their growth rate. To farther examine any morphological 
differences between WT and MT mice individual organ weights evaluated at two months 
of age. 
 
AIII. Results: 
When we crossed WT mice to the ARR2PPbi-Cre transgenic line, we noticed 
that the MT mice had an unexpected loss in longevity (Figure 3). The median lifespan of 
the MT mice was dramatically reduced (a median life span: 120 days). Both males and 
females showed comparable reductions in the life span. Careful examinations of the MT 
mice by a veterinary pathologist at MD Anderson Cancer Center failed to reveal any 
obvious pathological defects (data not shown).   
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Figure 3.  Deletion of the p44/WDR77 gene leads to decreased mouse life span.  
Survival data are presented for MT and WT mice.  The 50% survival mark was 120 
days for MT mice.   
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The MT mice appear morphologically identical to their WT littermates when they 
were born. However, the body weight increase of the MT mouse was less than that of 
the wild-type littermate by 60 days and stopped after 60 days (Figure 4). By 90 days, 
virtually all of the MT mice exhibit signs of an absence of vigor. Skin, spleen, liver, 
uterus, and prostate were significantly reduced in mass in the MT mice than in the age-
matched WT littermates (Figure 5). 
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Figure 4.  Deletion of the p44/WDR77 gene leads to decreased mouse growth rate.  
Comparison of mean body weights of WT and MT mice. 
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Figure 5.  MT mice exhibit early ageing-related decreases in organ weight.  
Comparison of mean organ weights of WT and MT mice.  Organs were removed form 
WT and MT mice at the age of two months and weight. 
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AIV. Discussion: 
These experiments demonstrated that the deletion of the p44/WDR77 gene 
driven by ARR2PPbi-Cre leads to a decrease in mouse longevity. This loss of longevity 
is suggestive of an accelerated aging phenotype associated with the MT mouse and 
additional support for this phenotype comes from the following observations. First, no 
obvious pathological defects were detected in the MT mouse. Second, the absence of 
increase in body weight and lacking vigor was observed in the young MT mice (2 
months old). Third and forth, two organs (skin and spleen) in the MT mice show the 
dramatic aging-related changes. The skin is the largest organ of the body, is 
significantly affected by the aging process and has been become a marker for aging. 
Thus the dramatic decrease in the weight of the skin in MT mice presents additional 
evidence of aging-related changes. This said age-related changes are more complex 
then a simple decrease in weight. The skin is composed of three layers the epidermis, 
dermis and subcutaneous tissue. Major components of age-related changes are 
decreases in adipose thickness and collagen atrophy in these layers (192). The spleen 
is the largest secondary immune organ in the human body and a multitude of studies 
have described the effects of aging on lymphocyte function and changes in the 
distribution of lymphocytes (193-196). Lymphocyte numbers and ability to undergo cell 
division can decrease with age. This is illustrated by an 80% decrease in lymphocyte 
numbers and general atrophy in the white pulp of spleens from older rats (197). Further 
supporting for a decrease in spleen size as a marker of aging comes from studies 
showing fewer germinal centers in older rodents (198). This being said a closer 
examination of the skin and spleen in MT mice is needed to confirm aging-related 
changes. Even still, these observations warrant further studies into what role 
p44/WDR77 might have in the mammalian aging process.    
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B. MT mice exhibit early ageing-related phenotypes.  
 
BI. Rationale: 
With the growing population of older adults understanding the mechanisms and 
nature of aging has become increasingly important. The loss of longevity in MT mice 
without obvious pathological defects with a striking decrease in spleen and skin size is 
suggestive of early aging in MT mice. In the skin age-related changes are marked with 
a decrease in dermal and subcutaneous adipose, accompanied with elasticity of the 
skin (192). Initial examination of the skin from MT mice showed that it was rigid and stiff 
when compared to the age-matched WT littermates, suggesting the loss MT skin weight 
might be due to decreased dermal and subcutaneous adipose. The spleens of aging 
rodents are marked by a notable decrease in the size of the white pulp indicative of a 
reduction in the number lymphocytes and lymphocytic cell division (193-197). While the 
decrease in spleen and skin weight is quite striking an aging phenotype is far more 
complex and further studies are needed to confirm an aging phenotype of the MT 
mouse. 
 
BII. Experimental Design: 
To examine the pathology of the spleen and skin from MT mice more closely we 
isolated spleens and skin from WT and MT mice at two months of age. Sections taken 
from fixed tissues underwent staining with Haematoxylin-esosin after which the dermal 
and spleen thickness and general tissue pathology was evaluated under a microscope. 
To examine proliferation in the WT and MT mice, mice were subjected to 
bromodeoxyuridine (BrdU) pulse (intraperitoneal injection, 100mg/kg) to label 
proliferating cells.  Skin and spleen sections were prepared 24 hours after the pulse and 
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cells that had incorporation BrdU (i.e. cells in S-phase) were identified by 
immunohistochemistry with anti-BrdU antibody. 
 
BIII. Results: 
Histological cross-sections of dorsal skin showed a dramatic reductions in 
dermal thickness and subcutaneous adipose cells were virtually absent in skin of the 2-
month-old MT mouse (Figure 6A, left panels). These differences in mouse skin were 
confirmed by weighing isolated whole skin from 2-month-old WT and MT mice (Figure 
5). Similarly, the spleen sections in 2-month-old MT mice are markedly reduced 
compared with those in the spleens of age-matched WT mice (Figure 6A, right panels; 
Figure 6B).   
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Figure 6.  The reduced thickness of spleen and loss of subcutaneous adipose 
tissue in the skin of MT mice. (A) Sections of dorsal skin and spleen of WT and MT 
mice at the age of two months were stained with Haematoxylin-esosin. (B) The 
subcutaneous adipose tissue in the WT skin is indicated by a parenthesis on the left.  
The quantitative data of the length of sections of WT and MT spleens are shown.   
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The immunohistochemistry with anti-BrdU antibody in skin and spleen sections 
taken from WT and MT mice, subjected to BrdU pulse (intraperitoneal injection, 100 
mg/kg) showed a decrease of cell of MT mice in S-phase (Figure 7A).  BrdU–posituve 
cells were quantified in skin and spleen sections illustrated that p44/WDR77 deficiency 
decreased proliferation (BrdU-positive cells) in the skin (from 28 ± 3/per field of view to 
5 ± 2/per field of view) and spleen (from 402 ± 41/per field of view to 168 ± 18/per field 
of view), a finding consistent with the observation that aging decreases cell proliferation 
in skin and spleen (Figure 7B). Thus, the MT mice display an onset of phenotypes 
associated with aging. 
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Figure 7.  The decreased proliferation rate in the skin and spleen of MT mice.  A, 
B. In vivo proliferation was assessed using the BrdU incorporation assay.  Sections of 
dorsal skin of WT (top) and MT (bottom) mice at the age of 2 months were 
immunostained with anti-BrdU antibody.  The BrdU-positive cells are stained brown (A) 
and quantitated (B). 
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BIV. Discussion: 
The experiments depicted in Figures 3 through Figure 7 suggest the presence of 
an accelerated aging phenotype in MT mice. This aging phenotype is supported by the 
lack of overt pathological defects in the MT mouse and, an ablation of body weight gain 
after post natal day 60 accompanied with a loss of vigor in MT mice. The phenotype is 
further demonstrated by a dramatic loss of dermal and subcutaneous adipose 
associated with fewer dividing cell in MT mice is indicative of an age-related phenotype 
seen in humans (192). Additionally the decrease in white pulp and the number of 
germinal centers coupled with a drop in proliferation in spleens from MT mice illustrates 
a possible age-related phenotype (197, 198). While a broader array of studies are 
needed to confirm the presence of an accelerated aging phenotype in MT mice, these 
experiments rationalize the need for additional studies into the roles p44/WDR77 in the 
regulation of mammalian aging process. 
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C. The p44/WDR77 gene was deleted in mouse brain.  
 
CI. Rationale:  
To gain a mechanistic understanding for the unexpected loss of longevity in MT 
mice we endeavored to identify the initiating tissue of this phenotype. Numerous studies 
have shown that surgical removal of the prostate along with physiologic disruptions in 
the prostate such as prostate cancer do not induce the aging like phenotype observed 
in MT mice (199, 200). This prompted the question as to whether the ARR2PPbi-Cre 
transgenic line is expressing Cre recombinase and inducing p44/WDR77 deletion in 
cells outside the prostate.   
Mice heterozygous or homozygous for the Gt(rosa)26tm1Sor targeted mutation 
have been useful for identifying tissues expressing Cre recombinase. B6;129-
Gt(37)26tm1Sor mice have a neo expression cassette flanked by loxP sites that prevents 
lacZ gene expression. Upon the induction of Cre recombinase expression the neo 
expression cassette is removed facilitating lacZ gene expression. This genetic alteration 
makes these mice an ideal model for the detection of Cre recombinase expression 
through identification of lacZ expression utilizing beta galactosidase staining (201).  
 
CII. Experimental Design: 
To investigate whether other tissues in addition to the prostate also express the 
Cre recombinase in the ARR2PPbi-Cre transgenic mouse, the status of p44/WDR77 
gene deletion was examined by sensitive PCR analysis. The heart, smooth muscle, 
skeletal muscle, liver, spleen, lung, kidney, skin, testis, small intestine, large intestine, 
pancreas, tongue, stomach, bone marrow, lymphnote, prostate, penis, eye, and brain, 
were isolated from WT and MT at two months of age. DNA was isolated from this panel 
of tissues and PCR analysis for p44/WDR77 gene deletion.  
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To confirm the gene deletion p44/WDR77 seen the PCR analysis was due to 
expression of Cre recombinase expression ARR2PPbi-Cre transgenic mouse, we 
crossed this mouse line with the B6;129-Gt(37)26tm1Sor mouse (The Jackson Laboratory, 
#003309).  Tissues were isolated from the B6;129-Gt(ROSA)26Sor/J (negative control) 
and B6;129-Gt(ROSA)26Sor/J-ARR2PPbi-Cre F1 heterozygous mice at two months of 
age. These tissues and tissue sections taken from where subject to galactosidase 
staining for the identification of lacZ expression. 
Additional studies were conduct to confirm that the Cre recombinase expression 
and deletion of p44/WDR77 correlated with a decrease in p44/WDR77 mRNA and 
protein. First, a Northern blot analysis was preformed using RNA isolated from brains 
from WT and MT mice at two months of age. Second, immunostaining analysis for 
p44/WDR77 protein was conducted using tissue sections taken brains from WT and MT 
mice at two months of age.    
 
CIII. Results: 
PCR analysis showed that the p44/WDR77 gene was deleted, as indicated by 
excision of the exons 2-5 of the p44/WDR77 gene, in the MT prostate gland but not in 
the WT prostate gland (Figure 8, lanes 2 and 3). This observation is consistent with 
expression of the Cre recombinase in the prostate as previously reported (191). The 
Cre-mediated deletion of the p44/WDR77 gene was also detected in penis, eye, and 
brain of the MT mouse (Figure 8, lanes 4, 5, 8, 9, 10, and 12). The p44/WDR77 alleles 
were not deleted in the other tissues (heart, smooth muscle, skeletal muscle, liver, 
spleen, lung, kidney, skin, testis, small intestine, large intestine, pancreas, tongue, 
stomach, bone marrow, lymphnote) examined in the MT mice (Figure 8, lanes 6, 7, 12, 
and 13; data not shown).   
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Figure 8.  The p44/WDR77 gene was deleted in mouse brain.  PCR analysis of the 
p44/WDR77 gene deletion in various organs in the MT mouse.  Genomic DNA was 
isolated from organs of WT and MT mice and submitted for the PCR analysis.   Excision 
of the exons 2-5 of the p44/WDR77 gene generated the 220-bp DNA fragment in the 
PCR reaction.  Lanes 1, the 0.1 kb DNA ladders.   
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In the experiments utilizing ARR2PPbi-Cre transgenic mouse crossed with the 
B6;129-Gt(37)26tm1Sor mouse (The Jackson Laboratory, #003309) we found as 
expected, the prostate stained strongly with beta galactosidase indicative of Cre 
recombinase expression. The brain also showed clear beta galactosidase staining 
(Figure 7, middle panel). Sections of the stained brain revealed that some cells were 
positively stained with beta galactosidase (Figure 9, left and right panels), indicating the 
Cre recombinase expresses in brain of the ARR2PPbi-Cre transgenic line. Consistent 
with the PCR analysis, the eye and penis were also found positively stained with -gal.   
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Figure 9.  Expression of the Cre recombinase in the brain of the ARR2PPbi-Cre 
transgenic mouse. The ARR2PPbi-Cre transgenic mouse was crossed with the 
B6;129-Gt(ROSA)26Sor/J mouse.  Brains were derived from B6;129-Gt(ROSA)26Sor/J 
(left of middle panel) or B6;129-Gt(ROSA)26Sor/J-ARR2PPbi-Cre (right of middle 
panel) mice at the age of two months and stained with -gal  (middle panel) and then 
formalin-fixed and paraffin-embedded.  Slides were county stained with Eosin (left and 
right panels).   
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Northern blot analysis shows the Cre-mediated loss of p44/WDR77 mRNA 
expression in the MT mouse brain (Figure 10A, top panels).  Immunostaining analysis 
demonstrated that p44/WDR77 protein levels were high in the nucleus in brain cells of 
the WT mouse (Figure 10B, top panel, indicated by arrows). These signals were 
dramatically reduced in brain cells of the MT mouse (bottom panel). Thus, these 
analyses indicate that the p44/WDR77 gene was deleted in the MT mouse brain and 
suggests the observed shorten lifespan in the MT mouse is possibly due to brain-
specific deletion of the p44/WDR77 gene. 
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Figure 10.  Loss of p44/WDR77 gene and protein expression in the MT mouse 
brain.  A, Northern blot analysis of p44/WDR77 and -actin mRNAs in the mouse brain.  
The mRNA was isolated from the brains of five WT (lane 1) or five MT (lane 2) mice at 
the age of two months, fractionated by electrophoresis, and transferred to a Hybond N+ 
membrane.  The membrane was hybridized with a p44/WDR77 probe (top panel) or -
actin probe (bottom panel).  B, Tissues derived from cerebral cortex of WT (top panel) 
and MT (bottom panel) of mouse brains were immunostained with anti-p44/WDR77 
antibody.  The nuclear staining of p44/WDR77 in WT mouse brain cells (indicated by 
arrows) was decreased in the MT mouse brain cells. 
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CIV. Discussion:  
The unexpected short longevity in the MT mouse prompted us to investigate the 
Cre expression in ARR2PPbi-Cre transgenic line and the Cre-mediated deletion of the 
p44/WDR77 gene in the MT mouse. We found that in addition to prostate, penis, and 
eye, the brain expresses high levels of Cre and shows the Cre-mediated deletion of the 
p44/WDR77 gene.  Surgical removal of the prostate along with physiologic disruptions 
in the prostate such as prostate cancer do not induce an accelerated aging like 
phenotype, suggesting the loss of the p44/WDR77 gene in the prostate is not the 
source of the aging like phenotype observed in MT mice (199, 200). Similarly while 
penile cancer can be life threatening and the surgical removal of the penis or 
penectomy can lead to a difficult recovery, it does not induce the aging like phenotype 
observed in MT mice (202, 203). Additionally surgical of the removal of the eyes or 
enucleation is an effective treatment for ocular cancer, and patients who have 
undergone these treatments do not exhibit the aging like phenotype observed in MT 
mice (204, 205). Further while ocular disease can elicit neural distress it has not been 
shown to stimulate the aging like phenotype observed in MT mice (206). While the brain 
a site of critical endocrine, immune, and system regulation, if disrupted or altered it 
could generate the phenotype observed in the MT mice (207). Thus, loss of 
p44/WDR77 expression in the brain is a possible drive of to the observed aging 
phenotype. 
To explore p44/WDR77 role in the brain more deeply we crossed WT with a 
Nestin-Cre transgentic mice. Nestin is expressed in brain neural progenitors at E8.5 and 
is down regulated at the end of neurogenesis (208). Nestin-Cre expression has been 
shown to be an effective means of achieving central nervous system-specific gene 
deletions (209).  A cross of the WT mouse with the mouse expressing Nestin-Cre led to 
embryonic lethalality, indicating the essential nature of p44/WDR77 in brain 
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development. The lack of a lethal phenotype in MT is indicative of the fact that only a 
subpopulation of brain derived cells are expressing Cre recombinase in MT mice. 
Suggests the loss of p44/WDR77 expression in a subset of cells the brain contributes to 
the observed aging phenotype. Consistent with these results, we observed in 
preliminary studies that down-regulation of p44/WDR77 expression was associated with 
aging in human brains (data not shown).  
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D. Deletion of the p44/WDR77 gene induces apoptosis in the brain.  
 
DI. Rationale:  
We have observed an unexpected loss in longevity in MT mice accompanied 
with Cre expression in the prostate, penis, eye and brain. The brain’s ability to directly 
regulate endocrine, immune and neural functions that can invoke metabolic and other 
system wide changes that can result in an aging phenotype makes it a likely candidate 
organ for the unexpected loss in longevity seen in MT mice (210-212). The aging brain 
is associated with increased neurodegeneration, and as excepted increased cell death 
can result in disruption of neural regulation (213-215). Additionally, previous studies 
have shown that the loss of the p44/WDR77 gene in the prostate gland increases 
apoptosis and alters the differentiation of epithelial cells (180, 181). Thus, loss of the 
p44/WDR77 gene might lead to apoptosis in mouse brain cells. 
 
DII. Experimental Design: 
To study the in vivo effects of loss of the p44/WDR77 genes on apoptosis in the 
mouse brain, five brains from WT and MT mice were isolated. The brains were fixed 
and sagittal sections at 0.00 (B3), 1.00 (B4), 2.00(B2 and B4), and 3.00 (B1 and B6) 
mm lateral planes were obtained. Slides were made from each section and subjected to 
TUNEL analysis and TUNEL positive cells were normalized to total (nuclear staining) 
number of cells per section.   
 
DIII. Results: 
MT brains showed a significant increase in TUNEL positive cells in every section 
examined (Figure 11). Consistent with the loss of longevity no difference between 
males and females were seen.  Additionally preliminary studies using double-stained for 
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TUNEL with MAP2 (staining neurons), suggest the majority of the apoptotic cells in the 
MT brain sections are neurons. These results suggest p44/WDR77 is important for 
neuron cell survival and possible neuroprotection.  
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Figure 11.  Deletion of the p44/WDR77 gene increased apoptosis in MT mice 
brains.  A, B,  Sagittal section at 0.00 (B3), 1.00 (B4), 2.00(B2 and B4), and 3.00 (B1 
and B6) mm lateral planes were taken from WT and MT mice brains at the age of 3 
months were subjected to Terminal deoxynucleotidyl transferase mediated dUTP nick 
end labeling (TUNEL) assay (A).  The Tunnel-positive cells indicated by white arrows 
(A) were quantitated (B). 
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DIV. Discussion:  
In these experiments we demonstrate that the loss of p44/WDR77 leads to 
increased cell death in the mouse brain. Additionally preliminary studies suggest that 
the majority of the apoptotic cells in the MT brain sections are neurons. The known 
association between aging and increased neural apoptosis and preliminary studies that 
show a decrease in p44/WDR77 in ageing human brains further strengthens an ageing 
like phenotype in MT mice (216, 217). A direct effect on neural survival would likely 
yield a focalized effect on neurons expressing Cre recombinase. The ubiquitous modest 
increase in apoptosis observed here is suggestive of an indirect glial effect on neural 
survival.    
Previous studies in our lab demonstrated the loss of the p44/WDR77 gene in the 
prostate gland increases apoptosis and alters the differentiation of epithelial cells (180, 
181). These studies suggest that p44/WDR77 has a direct or indirect role in regulating 
cell survival. Decreased glucocorticoids and androgens have been associated with an 
increased risk for neurodegenerative diseases (218, 219). Androgens and 
glucocorticoids down-regulate reactive gliosis after neural injury (220, 221).  
P44/WDR77 has the ability to act as a cofactor to modulate AR- or glucocorticoid 
receptor (GR)-dependent gene expression (180). Based on these observations, we 
anticipate that p44/WDR77 might mediate the suppressive effect of androgen or/and 
glucocorticoid on astrocyte activation.  It is also possible that p44/WDR77 might interact 
and function with other DNA-binding proteins in astrocytes. 
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E. Loss of the p44/WDR77 gene leads to reactive astrocytes in the mouse brain.  
 
EI. Rationale:   
We have observed an unexpected sharp reduction in the longevity of MT mice 
accompanied with Cre expression the brain. Preliminary studies show a decrease in 
p44/WDR77 in aging human brains, suggesting the loss in longevity is an aging like 
phenotype in MT mice. Additionally MT mice present with a ubiquitous increase in 
apoptosis in neuron cells, suggesting an indirect glial effect of p44/WDR77 on neural 
survival. This implies reactive astrogliosis might play a role in pathology and possibly 
the pathogenesis of MT mice.  
Increased reactive astrogliosis is an aspect of normal brain aging (222, 223). 
Additionally severe reactive astrogliosis has become a pathological marker of age-
related diseases such as Alzheimer, Parkinson, and Huntington (224-226). Molecular 
alterations that occur during reactive astrogliosis, can have both advantageous and 
disastrous effects invoked through the multitude of astrocyte function and subsequent 
secondary actions on the surrounding CNS environment (88, 89). These effects have 
been shown to directly affect patient outcome (39, 50, 85, 225). Thus a better molecular 
understanding of reactive astrogliosis could strengthen our quality of patient care. 
 
EII. Experimental Design: 
To examine reactive astrogliosis in MT mice we immunohistochemically stained 
brain tissues from WT and MT mice with p44/WDR77 and GFAP. Brains from WT and 
MT mice were isolated at 2 months of age. The brains were fixed and sectioned at 
lateral 2.00mm. The sections were first stained with a p44/WDR77 antibody to assess 
p44/WDR77 expression in astrocytes. The sections were then subjected to a stain for 
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GFAP. Astrocytes exhibiting strong GFAP expression and other morphologic features of 
reactive astrocytes were quantitated. 
 
EIII. Results: 
The p44/WDR77-positive signals in many astrocytes largely disappeared in the 
MT mouse brain (Figure 12A, panel b versus panel a). In WT mouse brain, only a few 
astrocytes (with strong GFAP staining and in spiny shapes) were reactive (Figure 12A, 
panel c, indicated by white arrows). In contrast, in MT mouse brain, more reactive 
astrocytes were noticed throughout the cerebral cortex (panel d, some are indicated by 
white arrows.). The cerebral cortex at the 2.00mm lateral plane in the MT mouse brain 
contained 1,560 ± 166 reactive astrocytes (Figure 12B). But the reactive astrocytes in 
the WT mouse brain were much less (280 ± 31 reactive astrocytes in the cerebral 
cortex at the 2.00 mm lateral plane). It is noticed that none of the reactive astrocytes 
expressed p44/WDR77 (Fig. 12A, panel f).  Thus, loss of p44 expression in mouse 
brain leads to reactive gliosis. 
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Figure 12.  Loss of the p44/WDR77 gene leads to reactive astrocytes in the mouse 
brain.  A, Reactive astrocytes were observed in the MT mouse brain.  The sections 
(lateral 2.00 mm) of cerebral cortex were derived from WT (left panels) or MT (right 
panels) brain and stained with anti-p44/WDR77 (top panels) or anti-GFAP (middle 
panels) antibodies.  The p44/WDR77 staining was merged with the GFAP staining 
(bottom panels).  Some reactive astrocytes are indicated by white arrows.  B, The 
quantitative data of reactive astrocytes in WT and MT brains are shown. 
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EIV. Discussion:  
These experiments revealed the expression of p44/WDR77 in astrocytes in the 
mouse brain and its expression was significant decreased in the MT mouse brain.  
Astrogliosis was only observed in astrocytes that had lost p44/WDR77 expression.  
While the significant increase in astrogliosis in the MT mouse brain could be the result 
of some other factor making the microenvironment unfavorable for neurons and 
astrocytes, the lack of p44/WDR77 expression in activated astrocytes suggests a role 
for p44/WDR77 in astrocytes activity.    
Previous studies in our lab have shown that prostate epithelial cells from MT are 
less differentiated relative to those in the wild-type litermates (181), suggesting 
p44/WDR77 plays a role in cellular differentiation and possibly astrocyte activation.  
While many of the detailed mechanisms of astrocyte activation remain to be elucidated, 
a number of pathways have been implicated in astrocyte activation (50). The effects of 
some of these pathways can be seen in studies that demonstrate decreased 
glucocorticoids and androgens are associated with an increased risk for 
neurodegenerative diseases. Androgen and glucocorticoid down-regulate reactive 
gliosis after neural injury (227-229).  P44/WDR77 has the ability to act as a cofactor to 
modulate AR- or glucocorticoid receptor (GR)-dependent gene expression (180). Based 
on these observations, we anticipate that p44/WDR77 might mediate the suppressive 
effect of androgen or/and glucocorticoid on astrocyte activation.  It is also possible that 
p44/WDR77 might interact and function with other DNA-binding proteins in astrocytes. 
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Chapter IV: Hypothesis and Aims 
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Rationale: 
Astrocytes have numerous critical functions in the CNS.  Additionally reactive 
astrogliosis has been shown to influence the clinical outcome in every form of CNS 
pathology. Despite decades of research on activated astrocytes and clinical implications 
in CNS insults the fundamental mechanisms about this phenomenon are just beginning 
to take shape (50).  
 Preliminary data demonstrated increased levels of reactive astrogliosis and 
cellular apoptosis in the brains of MT mice. The ubiquitous modest increase in CNS 
apoptosis observed in MT is suggestive of an indirect astrocyte effect on neural 
survival.  Recent studies have suggested that the AR-target gene p21Cip1 directly effects 
astrocytes activation (140, 141, 152, 172). This finding correlates with increased p21Cip1 
expression in MT mice brains illustrated in our whole brains gene array from MT and 
WT mice.  P21Cip1 has been implicated as a positive modulator of NF-B, a potent 
inflammatory transcription factor (132, 140, 141), suggesting the loss of p44/WDR77 in 
astrocytes might lead to deleterious effects on the CNS through the up regulation of 
p21Cip1 expression and subsequence NF-B activation (131, 140, 141).  P44/WDR77’s 
ability to regulate astrocyte activation through NF-B and p21Cip1 remains unexplored 
and represents a means to better understanding of and treatment of neurological 
pathologies (50). 
 
Hypothesis: 
Deletion of the p44/WDR77 gene induces astrocyte activation. 
 
Aims: 
Aim 1: To identity brain derived cells expressing p44/WDR77 
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Aim 2: To assess effects of p44/WDR77 on astrocyte activation 
Aim 3: To examine roles of p21Cip1 in astrocyte activation induced by the loss of 
p44/WDR77.  
Aim 4: To examine roles of NF-B activation in astrocyte activation induced by the loss 
of p44/WDR77. 
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Chapter V:   
Aim 1: To identity Brain-derived cells expressing 
p44/WDR77 
and  
Aim 2: To assess effects of p44/WDR77 on 
Astrocyte activation 
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A. Astrocytes in the brain express the p44/WDR77 protein. 
 
AI. Rationale: 
Astrocytes mediate numerous critical functions in the CNS.  Additionally reactive 
astrogliosis has been shown to influence the clinical outcome in every form of CNS 
pathology (50). These clinical observations highlight the need to understand the nature 
and molecular mechanisms of action that induce astrocyte activation and reactive 
astrogliosis. 
 Increased levels of reactive astrogliosis and cellular apoptosis are evident in the 
brains of MT mice.  To gain a mechanistic understanding for the unexpected induction 
of reactive astrogliosis and any roles of p44/WDR77 in the MT mouse brain we 
endeavored to learn the initiating cell type of this phenotype. The presence of 
p44/WDR77 in inactivated astrocytes along with its absence in activated astrocytes is 
suggestive of a direct involvement in astrocyte activation. Additionally the ubiquitous 
modest increase in CNS apoptosis observed in MT is suggestive of an indirect glial 
effect on neural survival. When endeavoring to understand what mechanistic steps are 
responsible for p44/WDR77-induced  reactive astrogliosis the first question is what cell 
types in brain are expressing p44/WDR77.  
  
AII. Experimental Design: 
To determine which cell types in the mouse brain express the p44/WDR77 
protein we double-immunostained stained brain tissues from WT mice with 
p44/WDR77-antibody and one of the two cellular markers NeuN (neurons) and GFAP 
(astrocytes). Brains from WT were isolated at 2 months of age. The brains were fixed 
and sectioned at lateral 2.00 mm. The sections were first stained with p44/WDR77-
antibody. The next day the sections were subjected to a second stain for GFAP to 
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examine p44/WDR77 expression in astrocytes or NeuN to examine p44/WDR77 
expression in neurons. Cells expressing p44/WDR77 and one of the two markers were 
quantitated per field of view under 20X magnification.  
 
AIII. Results: 
Population of the p44/WDR77 positive cells co-localized with GFAP staining 
(Figure 13), indicating that p44/WDR77 is expressed in astrocytes. Further 
immunostaining analysis with an anti-NeuN antibody indicated revealed that GFAP 
negative cell (indicated by white arrows) that stained positive for p44/WDR77 are 
neurons (Figure 14). Similar analysis indicates that p44/WDR77 is expressed in 
astrocytes of human brain tissues (Chemicon, TMA3001-4) data not shown. 
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Figure 13. P44/WDR77 expression in astrocytes of mouse brain.  A, B, Tissues 
were derived from cerebral cortex of the WT mouse brain were double-immunostained 
for p44/WDR77 (A) and GFAP (B). C, The GFAP staining signals are merged with 
p44/WDR77 staining. 
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Figure 14. P44/WDR77 expression Neurons of mouse brain. A, B, Tissues were 
derived from cerebral cortex of the WT mouse brain were double-immunostained for 
p44/WDR77 (A) and NeuN (B). C, The NeuN staining signals are merged with 
p44/WDR77 staining.  
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AIV. Discussion:  
These experiments revealed by immunostaining astrocytes and some neurons 
express p44/WDR77 in the mouse brain. With such broad level of expression of 
p44/WDR77 in NeuN positive neurons a dramatic increase in neural apoptosis would be 
excepted if the loss of p44/WDR77 was the primary cause for the increased apoptosis, 
contrary to the modest increase in CNS apoptosis seen in MT mice. Thus the ubiquitous 
modest increase in CNS apoptosis observed in MT suggests p44/WDR77 has an 
indirect effect on neural survival in brains of MT mice. However there are multitudes of 
ways where seemly subtle changes in neurons pathophysiology such as alteration in 
glutamate production could result in toxic environments which in turn generate both 
increased apoptosis and reactive astrogliosis (50, 104, 111). However many of these 
alterations would result in a focalized effect around the toxic environment, unlike the 
ubiquitous one that presents in the brains of MT mice (50). Despite these finding, it is 
not clear whether the loss of p44/WDR77 expression in astrocytes and/or in some 
neurons leads directly to the observed reactive astrogliosis.  
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B. Loss of p44/WDR77 expression leads to increased GFAP expression in 
astrocytes. 
 
BI. Rationale: 
Astrocytes, the most abundant cell type in the brain, were long believed to 
merely be a supportive component of the CNS and their activation was seen as a 
disease marker in the CNS (25, 38). Now, however they are appreciated for having 
critical roles in the health CNS, with both advantageous and disastrous effects during 
pathological states (39, 50). Even as their vast importance comes to light, many of the 
molecular mechanism that initiates the changes in astrocytes to induce advantageous 
or disastrous effects remain unclear (50). 
The loss of p44/WDR77 mediated by ARR2PPbi-Cre induces increased levels of 
reactive astrogliosis in the brains of MT mice.  We found that p44/WDR77 is expressed 
in inactivated astrocytes while astrocytes in an activated state do not express 
p44/WDR77. This result coupled with an ubiquitous modest increase in CNS apoptosis 
in MT mice, implies that p44/WDR77 plays a direct role in astrocyte activation. However 
this view is complicated by the presences of p44/WDR77 in NeuN positive neurons 
even with the lack of focalized astrogliosis and apoptosis in the brains of MT mice. This 
rationalizes a need to study MT and WT astrocytes in an environment independent of 
the effects of other cell types.  
 
BII. Experimental Design: 
To study MT and WT astrocytes independently of other brain-derived cells, 
primary astrocytes were isolated from newborn mouse cerebra cortex (184). These 
primary cells were grown in the tissue culture for five days, after which they were 
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transferred to chamber slides for immunostaining with anti-GFAP antibodies to confirm 
a pure population of astrocytes.   
To confirm the deletion of p44/WDR77 in primary MT astrocytes cells they were 
fixed in paraformaldhyde and embedded in low melting agarose (Sigma-Aldrich) and 
paraffin.  Section taken from the cell block underwent staining with anti-p44/WDR77 
antibodies. 
To assess astrocyte activation in WT and MT primary astrocytes cell lysates 
were prepared after five days of culture. These lysates were subjected to Western blot 
analysis with anti-p44/WDR77 and anti-GFAP antibodies. 
 
BIII. Results: 
Primary MT astrocytes could rarely be maintained in culture for more then 5 to 7 
days; in fact many of the astrocytes isolated from MT mice did not survive past the first 
day of culture. This result is contrary to primary WT astrocytes which could be 
maintained in tissue culture for over two weeks. 
The immunohistochemistry staining of primary astrocytes with anti-GFAP 
antibodies revealed that more than 95% of the cell culture population was GFAP-
positive cells (Figure 15A). While immunohistochemistry staining of primary WT 
astrocytes with anti-p44/WDR77 antibodies revealed that 100% of the astrocytes 
expressed p44/WDR77, only 50% of the primary astrocytes from MT mice expressed 
p44/WDR77 (Figure 16 A, B). 
Western blot assays using lysates from primary astrocytes demonstrated a 
significantly decreased expression of p44/WDR77 in astrocytes from MT mouse brain 
(Figure 15B, top panel, lane 2 versus lane 1). This decrease in p44/WDR77 expression 
correlated with an increase in GFAP expression (Figure 15B, bottom panel, lane 2 
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versus lane 1), suggesting that loss of the p44/WDR77 gene leads to astrocyte 
activation. 
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Figure 15. P44/WDR77 expression in primary astrocytes.  A, GFAP staining (green) 
of primary astrocytes in the tissue culture.  The nucleus was staining with DAPI.  B, Lost 
of p44/WDR77 expression in astrocytes isolated from the MT mouse brain.  The whole 
cell lysates (20 g protein) were made from astrocytes isolated from the WT (lane 1) 
and MT (lane 2) mice.  Western blot analysis was performed with anti-p44/WDR77 
(top), anti-GFAP (middle), or anti-actin (bottom) antibody. 
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Figure 16.  Some MT primary astrocytes express P44/WDR77. A, Primary astrocytes 
were isolated from MT and WT mice and stained for nuclear staining (a and d) and 
p44/WDR77 (b and e). Arrows indicate p44/WDR77 negative cells (c). The p44/WDR77 
staining signals are merged with nuclear staining (c and f).  B, The quantitative data of 
p44/WDR77 protein expression in WT and MT astrocytes are shown. 
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BIV. Discussion:  
The experiments depicted in Figure 12 demonstrated a significant increase in 
astrogliosis in the MT mouse brain, prompting us to investigate the role of p44/WDR77 
in astrocytes.  In vitro culture of primary astrocytes revealed a dramatic decrease in the 
survival of MT astrocytes, not seen in the brains of the adult MT mice. This discrepancy 
could be due to changes that occur from being in the culture; however this is unlikely to 
be the only cause for this loss of survival when considering the survival of WT 
astrocytes was unaffected in culture. Additional factors such as the lack of vascular 
clearance of toxic molecules being secreted from highly activated astrocytes could be 
contributing to this loss of survival (50). The possibility of the accumulation of toxic 
molecules induced by astrocyte activation was strengthened by increase in GFAP 
protein expression and inductive astrocytes activation correlated with a decrease in 
p44/WDR77 in MT astrocytes. Additional support for this toxic effect comes from the 
large number of MT astrocytes expressing p44/WDR77; suggesting p44/WDR77-null 
astrocyte can influence the survival of adjacent p44/WDR77 positive astrocytes. Thus, 
the mixed expression of p44/WDR77 in primary MT astrocytes complicates our 
understanding of the direct effects of the loss of p44/WDR77 on astrocyte function.  
While the mechanisms of action remain unclear the striking difference in GFAP protein 
expression and survival seen between WT and MT primary astrocytes illustrates that 
p44/WDR77 has a critical role in astrocyte activity. 
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C. Primary astrocytes isolated from MT mice brains have increased levels of 
apoptosis and cell division. 
 
CI. Rationale: 
Increased levels of reactive astrogliosis in the brains of MT mice, accompanied 
by up regulated GFAP expression associated with decreased p44/WDR77 in primary 
astrocyte suggest the loss of p44/WDR77 in astrocytes induces astrocyte activation. 
Considering the role of astrocytes in CNS physiology, p44/WDR77’s involvement in the 
their induction of activation as well as p44/WDR77’s known roles in the prostate 
prompts a deeper study into p44/WDR77 functions in astrocytic cellular proliferation and 
death (50, 179). This importance is compounded by our limited understanding of the 
mechanisms that induce proliferation in astrocytes, and the roles proliferating astrocytes 
have during severe reactive astrogliosis at blurring the boundaries between individual 
astrocytes and glial scaring (92, 50). 
 
CII. Experimental Design: 
To examine the effect of p44/WDR77 deletion on astrocyte proliferation, primary 
astrocytes were isolated from the brains of one day WT and MT mice. After 4 days 
culture the astrocytes were plated on a 100mm cell culture plate. 18 hours later the cell 
were pulsed with BrdU (10M) for 4 hours, followed by fixation and embedding in low 
melting agarose (Sigma-Aldrich). The sections were cut from these agarose pellets after 
being embedded in paraffin. Cells in S-phase cells in these sections were identified and 
quantitated by immunohistochemistry with anti-BrdU antibody. 
To study the in vitro effects of loss of the p44/WDR77 genes on apoptosis in 
astrocytes, primary astrocytes were isolated from the brains of one day WT and MT 
mice.  Following 5 days of the culture, astrocytes were fixed in paraformaldhyde and 
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embedded in low melting agarose (Sigma-Aldrich) and paraffin. Section taken from the 
fixed-cell block was submitted to TUNEL analysis. 
 
CIII. Results: 
The immunohistochemistry with anti-BrdU antibody showed an increase of 
proliferative cells in MT astrocytes compared to the WT astrocytes (Figure 17). BrdU–
positive cells were quantified in WT and MT astrocytes and p44/WDR77 deficiency 
increased proliferation (BrdU-positive cells) in astrocytes (from 8 ± 3/per 100 cells to 16 
± 2/per 100 cells), a finding consistent with increased GFAP expression that suggest 
astrocyte activation (Figure 17).   
 90
Figure 17.  Increased proliferation in MT astrocytes.  BrdU-positive cells from MT 
and WT astrocytes were quantitated 
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TUNEL analysis of WT and MT astrocytes revealed an increase in apoptotic MT 
astrocytes (Figure 18). TUNEL–positive cells were quantified in WT and MT astrocytes 
demonstrated that p44/WDR77 deficiency increased apoptosis (TUNEL-positive cells) in 
astrocytes (from 5 ± 1/per 100 cells to 11 ± 1/per 100 cells) with a p value of less than 
0.05 by student test, a finding consistent with the poor survival of survival observed in 
primary culture of MT astrocytes (Figure 18). 
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Figure 18. The increased apoptosis in MT astrocytes.  TUNEL-positive cells from 
MT and WT astrocytes were quantitated. 
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CIV. Discussion:   
These experiments demonstrate that the loss of p44/WDR77 in astrocytes leads 
to increased cell death and cell division. These results are consistent with prior studies 
in our lab that demonstrated the loss of the p44/WDR77 gene in the prostate gland 
increases proliferation and apoptosis and alters the differentiation of epithelial cells 
(180, 181).  Additionally these finding with the results from experiments depicted in 
Figures 12 through Figure 15 and studies by others that illustrate some state of 
astrocytes activation induce astrocyte proliferation and apoptosis, suggest that the loss 
p44/WDR77 leads to astrocytes activations. While our understanding of astrocyte 
proliferation and survival during activational states still remain unclear, p44/WDR77 
could be directing regulatory actions through the androgen regulated genes endothelin-
1 and p21Cip1 (152, 172, 179, 230). The lack of a dramatic increase in astrocyte 
apoptosis in the brains of MT mice complicates our understanding of the direct affects 
the loss of p44/WDR77 to has on astrocyte proliferation and apoptosis. The lack of a 
significant increase in astrocyte apoptosis in the brains of MT mice might be explained 
by changes induced by cell culture or the mice with exhibiting high Cre recombinase are 
dying prior to TUNEL analysis of the whole brain. Even still the mix expression of 
p44/WDR77 in primary MT astrocytes further complicates the interpretation and raising 
the questions as to whether the increased proliferation and apoptosis observed in these 
experiments are secondary effects arising from changing in the secretion of signaling 
molecules being released from 44p/WDR77 deficient astrocytes, acting on WT 
astrocytes or a direct affect by 44p/WDR77 on astrocyte function. 
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D. Loss of the p44 gene increased apoptosis and decreased proliferation of 
astrocytes.  
 
DI. Rationale: 
During severe reactive astrogliosis proliferating astrocytes fuse with other glial 
cells, fibroblast and the cellular architecture of the surround CNS to give birth to glial 
scars (100, 102). While glial scars can act as neuroprotective barriers that isolate 
deleterious agents, they are permanent markers of CNS severe reactive astrogliosis 
that hinder axonal regeneration and patient recovery (94, 95, 99, 103). The experiments 
illustrated in Figures 12 through Figure 15 suggest that the loss p44/WDR77 leads to 
astrocyte activations. Additionally primary MT astrocytes showed increased levels of 
cell growth and death (Figures 17 and 18), suggesting p44/WDR77 has a role in 
regulating the poorly understood pathways of astrocyte apoptosis and proliferation (50). 
These findings were complicated by mixed expression of p44/WDR77 in primary MT 
astrocytes. These limitations rationalize a need to study astrocytic functions in a system 
containing a pure population of p44/WDR77 deficient astrocytes. 
 
DII. Experimental Design: 
To further study p44/WDR77 function, astrocytes were isolated from 
p44/WDR77loxP/loxP mouse brains and immortalized with a vector expressing E6/E7 
(185). E6 protein interacts with p53 resulting in its degradation through the ubiquitin 
pathway, and E7 associates with Rb disrupting the interaction between Rb and E2F 
transcription factors, efficiently immortalizing cells (231, 232). Eight cell lines were 
obtained and all immortalized astrocytes express E6/E7. Two immortalized astrocyte 
cell lines (E3.1 and E3.2) were infected with either adenovirus Ad-CMV-GFP or Ad-
CMV-Cre–GFP to generate 4 cell lines (WT: E3.1 GFP, E3.2 GFP, MT: E3.1 Cre, E3.2 
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Cre). GFP expression was examined in the infected astrocytes under a fluorescent 
microscope. PCR analysis was used to confirm the deletion of the p44/WDR77 gene, as 
indicated by excision of the exons 2-5 of the p44/WDR77 gene, in the MT astrocytes but 
not in the WT astrocytes (Figure 18B inset). Nine days after infection MT and WT 
astrocytes were immunostained for p44/WDR77. After p44/WDR77 deletion was 
confirmed, astrocytes in culture were examined under 10X magnification from 9 day to 
12 day after adenovirus infection to assess the effects of the loss of the p44/WDR44 
gene on astrocytes structure.  
Then to examine the growth of MT astrocytes, cells were seeded to a 24-well 
plate and counted everyday from day 9 to day 13 post adenovirus infection. Twelve 
days after adenovirus infection, astrocytes were subjected to cytometric analysis of the 
cellular DNA content to further explore p44/WDR77 role in astrocyte growth and 
apoptosis.   
 
DIII. Results: 
Examination of GFP expression in the infected astrocytes revealed 100% 
infection efficiency three days post infection (Figure 19). 
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Figure 19.  The Cre recombinase-mediated deletion of the p44/WDR77 gene in 
astrocytes.  A, Diagram illustrates the procedure of astrocyte immortalization and 
p44/WDR77 gene deletion.  B, GFP expression in the adenovirus-infected WT and MT 
astrocytes 
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The immunohistochemistry with anti-p44/WDR77 antibody illustrated significant 
decreases in the levels of the p44/WDR77 protein in MT astrocytes 7 days post 
infection.  The p44/WDR77 signals in MT astrocytes were reduced to the level of the 
negative control (Figure 20B lower insert) 9 days post infection (Figure 20B). In 
contrast, p44/WDR77 expression in the WT astrocytes did not change upon adenovirus 
(Ad-CMV-GFP) infection (Figure 20E). 
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Figure 20.  Deletion of the p44/WDR77 gene in astrocytes.  A-F, Astrocytes were 
infected with Ad-CMV-GFP (WT) or Ad-CMV-Cre-GFP (MT) and stained for nucleus (A 
and D) and p44/WDR77 (B and E).  The p44/WDR77 staining signals are merged with 
nuclear staining (C and F).  The lower left corner of A-C depicts staining of WT without 
the p44/WDR77 antibody.  The upper right corner of B depicts PCR analysis of the 
p44/WDR77 deletion in WT and MT astrocytes.  
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The MT (E3.1 Cre, E3.2 Cre) astrocytes presented with a noticeable increase in 
the number of multinuclear cells (72%) (Some are indicated by black arrows), 
hypertrophy of cell nuclei and cytoplasmic regions (90%) (White arrows indicate some.) 
(Figure 21A, B, E, F). In contrast, the WT (E3.1 GFP, E3.2 GFP) astrocytes present 
with normal cellular structure (Figure 21C, D, G and H).  When the WT cells were 
approaching 100% confluency (on day 11), cells were split and continued to grow 
(Figure 19H). However, the MT astrocytes showed a steady decline in cellular density 
and never approached 100% confluency (Figure 21 E, F).  
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Figure 21.  Loss of the p44/WDR77 gene alters the cellular structure of astrocytes.  
A-H, WT and MT astrocytes were observed 9 (A and C), 10 (B and D), 11 (D and G), 
and 12 (F and H) days after adenovirus infection.  The upper left corners depict an 
enlarged region from panels indicated by black boxes. 
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 In the growth analysis WT (E3.1 GFP and E3.2 GFP) astrocytes cells continued 
to increase in cell number until day 12 when they reach confluency (Figure 22). The 
doubling times for E3.1 GFP and E3.2 GFP are 24 hours and 22 hours, respectively. In 
contrast, the MT (E3.1 Cre and E3.2 Cre) astrocytes presented with only a sight 
increase in cell number over the course of 5 days (Figure 22).  
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Figure 22.  Deletion of the p44/WDR77 gene inhibits growth.  Growth curves of WT 
(E3.1 GFP, E3.2 GFP) or MT (E3.1 Cre, E3.2 Cre) astrocytes.   
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The Cytometric analysis of the cellular DNA content revealed that the WT 
astrocytes were composed of 54.75% G1, 19.33% G2, and 25.93% S cells. However, 
the MT astrocytes were composed of 53.81% G1, 24.17% G2, and 22.02% S cells, 
indicating a slight G2 cell cycle arresting and less cell division (S phase) in the MT 
astrocytes. This analysis further demonstrated that the sub-G1 apoptotic peaks for MT 
cells were 41% of the total cell population (Figure 23B). A sharp increase over the 8% 
sub-G1 apoptotic peaks for WT cells (Figure 23B).   
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Figure 23.  Deletion of the p44/WDR77 gene inhibits growth and induces 
apoptosis in astrocytes.  A,B. Flow cytometry data with the sub-G1 area gated for 
apoptosis of WT (A) and MT (B) astrocytes 12 days post adenovirus infection.  
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DIV. Discussion:   
  P44/WDR77 expression was confirmed in the cultured astrocytes by 
immunostaining and PCR.  Furthermore, we demonstrated p44/WRD77 is required for 
growth of astrocytes and loss of p44/WDR77 expression led to dramatic changes in the 
cell structure which are characteristics of astrogliosis. This is consistent with our 
findings in primary MT astrocytes that exhibit increase apoptosis and changes in 
cytoskeleton proteins indicative of astrogliosis. The discrepancies between the 
experiments illustrated in Figure 17, which present a moderate increase in proliferation 
in MT astrocytes versus the dramatic decrease depicted in these experiments suggest 
the increased levels of proliferation in Figure 17 are a result of secondary effects arising 
from changes in the secretion of signaling molecules being released from p44/WDR77 
deficient astrocytes act paracrine fashion on WT astrocytes. A direct role for 
p44/WDR77 in astrocyte proliferation and apoptosis, are strengthened by previous 
studies that showed that the deletion of the p44/WDR77 gene in the prostate gland 
increased proliferation and apoptosis and altered the differentiation of epithelial cells 
(180, 181). Together these results suggest, that p44/WDR77 has a multitude of critical 
roles in the regulation of different cellular environments.  
MT astrocytes presented with a high percentage of multinuclear cells, 
hypertrophy of cell nuclei and cytoplasmic regions. These structural changes in MT 
astrocytes were accompanied with a state of near complete cessation. The abnormal 
nuclear and cellular morphology, and cell cycle variations seen in MT astrocyte are 
comparable to the altered cellular phenotype of mouse embryo fibroblast metaphases 
deficient in pituitary tumor transforming gene (PTTG) (233). This is consistent with gene 
array data from WT and MT brains, which illustrates strong alteration in PTTG 
expression in MT brains. PTTG modulates cell transformation, DNA repair, gene 
regulation, and mitosis in part through its involvement in the initiation of sister-chromatin 
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separation during the anaphase (233). In the CNS, PTTG has been implicated as 
important cell cycle regulator in neurogenesis and astrocytes (234, 235). P44/WDR77 
role as an AR cofactor coupled with the ability of AR to regulate PTTG gene expression 
(236) suggests a possible mechanism for the observed phenotype. However, the loss of 
PTTG expression did not result in the termination differentiation and cell death (233). 
P44/WDR77 must target other genes which mediate some astrocyte functions. 
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E. Deletion of the p44/WDR77 gene leads to astrocytes activation. 
 
EI. Rationale: 
Hallmark of reactive astrogliosis are up regulation of GFAP, cellular hypertrophy, 
and pro- or anti-inflammatory effects on the surrounding CNS tissue with primary and 
secondary affects on the disease pathology of the CNS with direct and even life 
threating implications in patient outcome (39, 50, 85). Answering even the most basic 
questions about astrogliosis has proven to be a challenge for even the best 
neurobiologists and neuroanatomists, therefore creating a need for a greater 
understanding of the underlining mechanisms in astrocyte activation (50).   
Increased astrogliosis seen in the brains in MT, along with changes in cellular 
structure of MT astrocytes have suggested a role for p44/WDR77 in astrocyte 
activation.  Initial studies of GFAP expression in MT astrocytes were conducted with 
astrocytes exhibiting varied expression of p44/WDR77. The studies of proliferation were 
conducted with astrocytes with varied expression of p44/WDR77 complicating our 
interpretation of the direct effects of p44/WDR77.   
 
EII. Experimental Design: 
To further study p44/WDR77’s role in astrocyte activation E6/E7 immortalized 
astrocytes were infected with either Ad-CMV-GFP (WT) or Ad-CMV-Cre–GFP (MT).  
PCR analysis was used confirmed the deletion of the p44/WDR77 gene, as indicated by 
excision of the exons 2-5 of the p44/WDR77 gene, in the MT astrocytes but not in the 
WT astrocytes (Figure 20B insert). Nine days after infection MT and WT astrocytes 
were immunostained for GFAP. 
 
EIII. Results: 
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Previous studies demonstrated that immortalized astrocytes express low levels 
of GFAP and show cellular structure of nonreactive astrocytes (237). Consistent with 
these observations, WT immortalized astrocytes exhibited low levels GFAP and cellular 
structure of nonreactive astrocytes (Figure 24E). Upon loss of p44/WDR77 expression 
(9 days post infection), the MT astrocytes expressed much higher levels of GFAP 
(Figure 22B), suggestive of astrocyte reactivity. The hypertrophy of cell nuclei and the 
thin processes protruding the cell body were evident in the MT astrocytes (Figure 24A-
F), which are characteristics of astrocyte activation (50). These observations are 
consistent with the primary astrocytes isolated from the MT mouse brains expressing 
much higher levels of GFAP expression than those isolated from the WT mouse brains 
(Figure 15B, middle panel, lanes 2 versus lane 1). 
 
 109
Figure 24.  Deletion of the p44/WDR77 gene in astrocytes leads to increased 
GFAP expression. A-F, WT and MT astrocytes were stained for nucleus (A and D) and 
GFAP (B and E).  The GFAP staining signals are merged with nuclear staining (D and 
F). 
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EIV. Discussion:   
The significant increase in astrogliosis in the MT mouse brain led us to 
investigate the role of p44/WDR77 in astrocytes. Expression of p44/WDR77 in 
astrocytes was revealed by immunostaining in the mouse brain and its expression was 
decreased in the MT mouse brain. Astrogliosis was only observed in astrocytes that had 
lost p44/WDR77 expression. Furthermore, we demonstrated p44/WRD77 is required for 
growth of astrocytes and loss of p44/WDR77 expression led to dramatic changes in the 
cell structure and increased expression of GFAP, which are characteristics of 
astrogliosis. Thus, p44/WDR77 prevents astrogliosis in the brain.   
While the mechanisms of astrocyte activation still remain quite unclear, there are 
a number of pathways by which p44/WDR77 could drive astrocytes into an activational 
state (50). P44/WDR77’s ability to act as a cofactor to modulate AR- or GR 
transcriptional activity may be one mechanism (180). GR is a potent repressor of NF-B 
activity, which has been implicated in the regulation of astrocyte activation, thus 
presenting a possible mechanism of action for p44/WDR77 (132-134, 238). Additionally 
a more recent study suggested that p21 plays a role in astrocyte activation (140, 141). It 
has been demonstrated that AR and p44/WDR77 target the p21 promoter (152, 172), 
consistent with the whole brain gene array that demonstrated a significant increase in 
p21 expression in the MT mouse brain as well as in the p44-null astrocytes.   
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Chapter VI:   
Aim 3: To examine the role of p21Cip1 in astrocyte 
activation induced by the loss of p44/WDR77. 
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A. p21Cip1 is over expressed in activated astrocytes induced by the loss of 
p44/WDR77. 
 
AI. Rationale: 
Despite decades of research on activated astrocytes and pathological 
implications of CNS insult the fundamental mechanism underlying this phenomenon is 
just beginning to take shape (50). The studies depicted in Figures 12 – 24 illustrate that 
the deletion of the p44/WDR77 gene in astrocytes induces astrogliosis characterized by 
a vast increase in GFAP, along with other morphological and physiological changes 
indicative of astrocyte activation (50), suggesting that p44/WDR77 has a role in the 
induction of astrocyte activation.  
P44/WDR77’s known modulation of AR functions may be one means by which it 
exerts its control over astrocytes activation. This possibility is illustrated by androgens’ 
ability to down-regulate reactive gliosis after neural injury (227, 228).  Recent studies 
have suggested that the p21Cip1 directly affects astrocyte activation induced by LPS 
(140, 141, 152, 172). This finding correlates with a 4 fold increase p21Cip1 expression in 
MT mice brains found in our gene array of whole brains from MT and WT mice. 
 
AII. Experimental Design: 
To examine p21Cip1 expression in mice brains, total RNA was isolated from 
whole brains of MT and WT mice at 3 months of age. The RNA was subjected to 
Northern blot analysis for p21Cip1. 
To assess p21Cip1 expression in astrocytes, immortalized astrocytes were 
infected with either Ad-CMV-GFP or Ad-CMV-Cre–GFP. Seven days after infection total 
RNAs were isolated and subjected to qRT-PCR with primers for p21Cip1. 
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AIII. Results: 
Correlating with DNA microarray data the northern blot analysis showed that 
Cre-mediated deletion of p44/WDR77 increased (5 fold) expression of p21Cip1 mRNA in 
the MT mouse brain (Figure 25, lanes 3 and 4). The up regulation of p21 gene is not 
through the p53 pathway since expression of the other p53-target genes (Gadd45A and 
RGS16) did not change in the MT mouse brain (lanes 5-8). The qRT-PCR analysis 
revealed a 4.5-fold increase in p21Cip1 mRNA expression in MT astrocytes than that in 
WT astrocytes. 
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Figure 25. Deletion of the p44/WDR77 gene increases p21Cip1 RNA expression in 
astrocytes.  A, Northern blot analysis of p21Cip1 and -actin mRNAs in the mouse brain.  
The mRNA was isolated from the brains of five MT (lanes 1, 3, 5, 7, 9) or five WT (lanes 
2, 4, 6, 8, 10) mice at the age of three months, fractionated by electrophoresis, and 
transferred to a Hybond N+ membrane.  The membrane was hybridized with a p44, 
p21Cip1, Gadd45A, RGS16, or -actin probe.   
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AIV. Discussion:  
To explore p44/WDR77 mechanistic roles in astrocyte activation we examined 
p21Cip1 RNA expression in MT mouse brains. We found that p21Cip1 RNA expression 
was up regulated in MT mouse brains. The interpretation of this finding is complicated 
by potential indirect activation secondary to induced neural growth factors and cytokines 
which can in turn directly affect the activity and expression of cell cycle regulators such 
as p21Cip1 (239-242, 50). To overcome some these complications we examined p21Cip1 
RNA expression in MT astrocytes.  Similar to the northern blot and DNA microarray 
analysis we found an increase in p21Cip1 RNA expression in MT astrocytes. Consistent 
with regulation of p21Cip1 expression by AR (152), we found a reduction in androgen-
mediated up regulation of p21Cip1 expression in MT astrocytes, suggesting that 
p44/WDR77 can influence astrocyte activation by enhancing AR-driven repression of 
p21Cip1 gene.  However this does not prelude secondary effects on p21Cip1 expression 
that occur during astrocyte activation. Such is the case with NF-B, a powerful 
inflammatory transcription factor, which has long been implicated in astrocyte activation 
which can control p21Cip1 in a p53 dependent and independent manner (50, 136).  
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B. Over expression of p21Cip1 contributes to the decrease in astrocyte growth 
induced by deletion p44/WDR77. 
 
BI. Rationale: 
Cell growth and the progression through the cell cycle are orchestrated by the 
harmonized interaction of cyclin/cyclin-dependent kinases (CDK) complexes.  P21Cip1 is 
a powerful CDK inhibitor (CKI). Through protein-protein interactions with cyclin-CDK2 or 
-CDK4 complexes p21Cip1 directly inhibits their activity, and in doing so acts as a 
regulator of cell cycle progression at G1 (243, 244).  We found that p21Cip1 expression is 
up regulated in astrocyte activation induced by deletion of the p44/WDR77 gene (Figure 
25). Given the well known function of p21Cip1 in cell growth control and the striking 
decrease in astrocyte growth in p44/WDR77-null astrocytes (Figure 22), further 
exploration of the interaction between these two molecules represents a mean to add to 
the elucidation of the molecular mechanisms in astrocyte activation. 
 
BII. Experimental Design: 
To determine the role of p21Cip1 in astrocyte growth during astrocytes activation 
induced by the loss of p44/WDR77, p21Cip1 expression was silenced by shRNA in WT 
astrocytes infected with lentivirus expressing a nontargeting sequence or p21Cip1 
shRNA. To assess the infection efficiency GFP expression was examined in the 
astrocytes under a fluorescent microscope. Four days later the infected astrocytes were 
infected with either Ad-CMV-GFP or Ad-CMV-Cre–GFP to generate 4 cell lines (WT: 
Control shRNA-GFP, p21Cip1 shRNA-GFP, MT: Control shRNA-Cre, p21Cip1 shRNA-Cre) 
(Figure 26A). Then cell growth of these lines was examined by plating the cells in a 24-
well plate and counting everyday from day 9 to day 13 post adenovirus infection. 
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To further explore p21Cip1 roles in astrocyte growth, WT astrocytes were infected 
with lentivirus expressing human p21Cip1 (Figure 26B). Then the cell growth of these 
lines was examined by seeding the cells to a 24-well plate and cells were counted daily 
from day 9 to day 13 post infection. 
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Figure 26. Experimental design for p21Cip1silencing and over-expressing and 
p44/WDR77 gene deletion in astrocytes. A, Diagram illustrates of p21Cip1 silencing in 
astrocytes. B, Diagram illustrates p21Cip1 over-expression in astrocytes. 
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To confirm knockdown and over expression of p21Cip1 whole cell lysates were 
prepared 7 days after adenovirus infection, and subjected to Western blot analysis with 
anti-p21Cip1 or anti--actin antibody.  
 
BIII. Results: 
Examination of lentivirus infection revealed 90% infection efficiency three days 
after infection (Figure 27). 
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Figure 27. Lentivirus infection of astrocytes. A, Diagram illustrates the procedure of 
silencing p21Cip1 expression in astrocytes. B, GFP expression in astrocytes infected with 
lentivirus expressing the Control shRNA or p21Cip1 shRNA. 
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Consistent with qRT-PCR the Western blot analysis revealed a 4 fold increased 
expression of p21Cip1 associated with the loss of p44/WDR77 (Figure 28A, top panel, 
lane 5 versus lane 1), while no detectable difference in p21Cip1 expression was found in 
Control-GFP and p21Cip1 shRNA-GFP astrocytes (Figure 26A, top panel, lane 2 versus 
lane 1). In contrast, p21Cip1 shRNA expression significantly reduced expression of 
p21Cip1 in astrocytes after gene deletion of the p44/WDR77 gene (Figure 28A, top panel, 
lane 6 versus lane 5). 
In the growth analysis p44/WDR77 WT (Control and p21Cip1 shRNA expressing) 
astrocytes continued to increase in cell number until day 12 when they reach 
confluency. The doubling times for Control-GFP, p21Cip1 shRNA-GFP are 26 and 22 
hours, respectively.  However, silencing of p21Cip1 expression (p21Cip1 shRNA-Cre) 
partially restored the growth of p44/WDR77-null astrocytes (Control-Cre). P21Cip1 
shRNA-Cre astrocytes had a doubling time of 31 hours and didn’t reach confluency 
during the five days assayed. The p44/WDR77-null (Control-Cre) astrocytes showed 
only a sight increase in cell number over the course of 5 days (Figure 28B). 
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Figure 28. Down regulation of p21Cip1 expression partially restores growth of 
p44/WDR77 deficient astrocytes.  A, The whole cell lysates (20 g protein) were 
made from WT astrocytes: the Control-GFP, p21Cip1 shRNA-GFP, p65 shRNA-GFP, 
p21Cip1 shRNA + p65 shRNA-GFP (lanes 1-4) and MT astrocytes: Control-Cre, p21Cip1 
shRNA-Cre, p65 shRNA-Cre, p21Cip1 shRNA + p65 shRNA-Cre (lanes 5-8).  Western 
blot analysis was performed with anti-p21Cip1 (first panel), anti-p65 (second panel), anti-
GFAP (third panel), or anti-actin (fourth panel) antibody.  B, Grow curves of WT 
(Control-GFP, p21Cip1 shRNA-GFP) and MT (Control-Cre, p21Cip1 shRNA-Cre) 
astrocytes.   
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Western blot analysis of confirmed expression of human p21Cip1 in p21Cip1-
expressing astrocytes (Figure 29A top panel, lane 2 versus lane 1). 
 Human p21Cip1 expression decreased growth of astrocytes (Figure 29B). The 
doubling times for Control and p21Cip1-expressing are 24 and 30 hours, respectively. 
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Figure 29.  P21Cip1 over expression decreases growth of astrocytes.  A, The whole 
cell lysates (20 g proteins per sample) were made from Control (lane 1), p21Cip1 over 
expression (lane2), p65 over expression (lane3), p21Cip1 + p65 over expression (lane4) 
astrocytes.  Western blot analysis was performed with anti-p21Cip1 (first panel), anti-p65 
(middle panel) or anti-actin (bottom panel).  Arrows on the right indicate endogenous 
mouse p21Cip1 and exotic human p21Cip1, respectively.  B, Grow curves of Control, 
p21Cip1 over expression, and p44/WDR77-null astrocytes.   
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BIV. Discussion:  
Previous experiments illustrated that the deletion of the p44/WDR77 gene 
induced a dramatic decrease in growth in astrocytes (Figure 22). While the p21Cip1 
shRNA did not appear to affect the low levels of p21Cip1 expression in the WT 
astrocytes, the p21Cip1 shRNA was effective at knocking down the high levels of p21Cip1 
expression in the p44/WDR77-null astrocytes and partially restored growth of 
p44/WDR77-null astrocytes (Control-Cre). These experiments demonstrate that the up 
regulation of p21Cip1 is partially responsible for the dramatic decrease in growth of 
astrocytes induced by loss of p44/WDR77. Furthermore we confirmed the ability of 
p21Cip1 to directly decrease astrocyte growth through the over expression of human 
p21Cip1 which is functional conserved to mice (244, 245). These findings suggest that 
p44/WDR77 regulates astrocyte proliferation through decreasing p21Cip1 expression. 
This is consistent with the well established role of p21Cip1 as a potent regulator of cell 
growth and cell cycle (243, 244).  
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C. P21Cip1 over-expression is essential for astrocyte activation induced by 
p44/WDR77 gene deletion. 
 
CI. Rationale:  
The fundamental molecular mechanism that guide the induction of reactive 
astrogliosis and how they affect astrocytic function, are just beginning to come to light 
(50). Prior experiments in this study (Figure 12 – 24) illustrated that deletion of 
p44/WDR77 gene in astrocytes induces astrogliosis characterized by the hallmark 
increase in GFAP. We found that the loss of p44/WDR77 in astrocytes generated a 4 to 
5 fold increase in p21Cip1 expression (Figure 28B). This finding coupled with recent 
studies that demonstrated over-expression of p21Cip1 is associated with astrocyte 
activation (140, 141) suggests p44/WDR77 might be influencing astrocyte activation 
through the regulation of p21Cip1. 
 
CII. Experimental design: 
To examine p21Cip1 roles in astrocyte activation induced by the loss of 
p44/WDR77, p44/WDR77loxP/loxP astrocytes were infected with lentivirus expressing a 
nontargeting control or p21Cip1 shRNA (Figure 27A). Four days later the control and p21 
shRNA-expressing astrocytes were infected with either Ad-CMV-GFP or Ad-CMV-Cre–
GFP to generate 4 cell lines (WT: Control-GFP, p21Cip1 shRNA-GFP, MT: Control-Cre, 
p21Cip1 shRNA-Cre) (Figure 26A). Nine days after infection, astrocytes were 
immunostained for GFAP. Cell lysates were also prepared from astrocytes seven days 
after adenovirus infection and subjected to Western blot analysis with anti-GFAP 
antibody.   
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To further explore p21Cip1 roles in astrocyte activation, WT astrocytes were 
infected with the control lentivirus or lentivirus expressing the human p21Cip1. Nine days 
post virus infection astrocytes were subject to immunostaining for GFAP. 
 
CIII. Results: 
Comparable with earlier findings, p44/WDR77 WT (Control-GFP, p21Cip1 shRNA-
GFP) astrocytes exhibited low levels of GFAP and resembled nonreactive astrocytes 
(Figure 30B, H). Upon the loss of p44/WDR77 expression (9 days post Ad-Cre-GFP 
infection), the p44/WDR77-null (Control-Cre) astrocytes expressed much higher levels 
of GFAP with cellular and nuclear hypertrophy (Figure 28E), indicative of astrocyte 
reactivity while p21Cip1-silenced (p21Cip1 shRNA-Cre) astrocytes, despite the loss of 
p44/WDR77, showed low levels GFAP and cellular structure of nonreactive astrocytes 
(Figure 30K). This finding was confirmed in the Western blot analysis which illustrates a 
hallmark increase of GFAP in Control-Cre astrocytes while the p21Cip1 shRNA-Cre 
astrocytes maintain basil level of GFAP expression (Figure 28A, third panel, lane 5 and 
6). 
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Figure 30. Down regulation of p21Cip1 expression inhibits astrocyte activation 
induced by deletion of p44/WDR77 gene.  A-F, WT (Control-GFP) and MT (Control-
Cre) astrocytes were stained for nucleus (A and D) and GFAP (B and E).  The GFAP 
staining signals are merged with nuclear staining (D and F).  G-L, WT (p21Cip1 shRNA-
GFP) and MT (p21Cip1 shRNA-Cre) astrocytes were stained for nucleus (G and J) and 
GFAP (H and K).  The GFAP staining signals are merged with nuclear staining (I and 
L). 
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Consistent with prior studies (140, 141) that suggest p21Cip1 is involved in 
astrocyte activation, we found that p21Cip1 over expression moderately increased GFAP 
expression and induce cellular structure of activated astrocytes (Figure 31E), while the 
control astrocyte maintained low levels GFAP and cellular structure of nonreactive 
astrocytes (Figure 31B).   
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Figure 31. P21Cip1 over expression leads to increased GFAP expression in 
astrocytes.  A-F, Control and p21Cip1 over expression astrocytes were stained for 
nucleus (A and D) and GFAP (B and E).  The GFAP staining signals are merged with 
nuclear staining (D and F). 
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CIV. Discussion: 
The significant increase in astrogliosis in the p44/WDR77-null mouse brain and 
astrocytes accompanied with increased p21Cip1 expression led us to determine whether 
44/WDR77 represses astrocyte activation through the regulation of p21Cip1 expression. 
Immunostaining revealed the induction of astrogliosis by p44/WDR77 gene deletion 
only in astrocytes expressing high levels of p21Cip1. Further more we confirmed the 
ability of p21Cip1 to induce astrocytes activation independent of p44/WDR77 status, 
through over expression of human p21Cip1 (140, 141). These results suggest that 
p44/WDR77 influences astrocyte activation through the regulation of p21Cip1 expression. 
However, the p21Cip1 over expression in astrocytes did not induce the level of GFAP 
expression generated by p44/WDR77 deletion in astrocytes. This could be due to the 
possibility that the p44/WDR77 controls astrocytes activation not only through p21Cip1 
but also via other factors. While there is growing evidence that cell-cycle control 
systems have regulatory functions in reactive gliosis, the mechanistic actions of p21Cip1 
in reactive gliosis remain incompletely characterized (246-248).  P21Cip1 has positive 
modulatory effects on NF-B activation a pathway long implicated in gliosis; represent 
an additional possible contributing mechanism (140, 141). 
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D. P21Cip1 is a positive modulator of NF-B during astrocyte activation induced by 
p44/WDR77 gene deletion. 
 
DI. Rationale: 
A greater molecular understanding of the induction and regulatory control of the 
dual nature of astrogliosis as both detrimental and beneficial would vastly improve the 
treatment of CNS damage (50). We have observed an increase p21Cip1 expression 
associated with astrocyte activation induced by the gene deletion of p44/WDR77.  Upon 
further examination, we found that inhibition of p21Cip1 up regulation in astrocytes after 
p44/WDR77 deletion inhibits astrocyte activation. From this point, we conclude that 
p44/WDR77 influences astrocyte activation through the regulation of p21Cip1 expression. 
Recent studies implicated p21Cip1 as a positive modulator for NF-B, a potent 
inflammatory transcription factor (132, 140, 141), suggesting that the loss of 
p44/WDR77 in astrocytes might have deleterious effects on the CNS through the up 
regulation of p21Cip1 expression and subsequent NF-B activation (131, 140, 141). 
 
DII. Experimental design: 
To examine p21Cip1 regulatory effects on NF-B activity in astrocytes activation 
induced by the loss of p44/WDR77, p44/WDR77loxP/loxP astrocytes were infected with 
lentivirus expressing nontargeting control or p21Cip1 shRNA. Four days later the control 
and p21 shRNA-expressing astrocytes were infected with either Ad-CMV-GFP or Ad-
CMV-Cre–GFP to generate 4 cell lines (WT: Control-GFP, p21Cip1 shRNA-GFP, MT: 
Control-Cre, p21Cip1 shRNA-Cre) (Figure 24A). Nine days after virus infection astrocytes 
were immunostained for p65.   
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To further explore p21Cip1 roles on NF-B activity in astrocyte, WT astrocytes 
were infected with control lentivirus or lentivirus expressing the human p21Cip1. Nine 
days after infection astrocytes were immunostained for p65. Cell lysates were also 
prepared seven days after virus infection and subjected to western blot analysis with 
anti-p65. 
 
DIII. Results 
Immunostaining of p44/WDR77 WT (Control-GFP, p21Cip1 shRNA-GFP) 
astrocytes revealed low cytoplasmic levels of p65 (Figure 32B, H). Nine days after 
infection, the p44/WDR77-null (Control-Cre) astrocytes expressed high nuclear levels of 
p65 (Figure 30E), indicative of NF-B activation while the silencing of p21Cip1 expression 
in p21Cip1 shRNA-Cre astrocytes inhibited NF-B activation induced by p44/WDR77 
gene deletion (Figure 32K). However, Western blot analysis indicated that shRNA 
knockdown of p21Cip1 failed to prevent an increase of p65 expression induced by 
p44/WDR77 gene deletion (Figure 28A, second panel, lane 5 versus lane 6), 
suggesting that p44/WDR77 can also regulate p65 expression independent of p21Cip1. 
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Figure 32. Down regulation of p21Cip1 expression decreases p65 nuclear 
localization induced by p44/WDR77 deletion in astrocytes.  A-F, WT (Control-GFP) 
and MT (Control-Cre) astrocytes were stained for nucleus (A and D) and p65 (B and E).  
The p65 staining signals are merged with nuclear staining (D and F).  G-L, WT (p21Cip1 
shRNA-GFP) and MT (p21Cip1 shRNA-Cre) astrocytes were stained for nucleus (G and 
J) and p65 (H and K).  The p65 staining signals are merged with nuclear staining (I and 
L).  
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In line with studies (140, 141) that implicate p21Cip1 as positive modulator of p65, 
we found that p21Cip1 over expression increased p65 protein expression (Figure 33E), 
while control astrocyte maintained low levels p65 (Figure 33B). This observation was 
strengthened by Western blot analysis that revealed p21Cip1 over expression increased 
p65 expression in astrocytes (Figure 29A, middle panel, lane 2 versus lane 1). 
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Figure 33. P21Cip1 Over expression leads to increased p65 nuclear localization and 
expression in astrocytes.  A-F, Control and p21Cip1 over expression astrocytes were 
stained for nucleus (A and D) and p65 (B and E).  The p65 staining signals are merged 
with nuclear staining (D and F). 
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DIV. Discussion: 
Activation of the canonical or classical NF-κB pathway has been implicated in 
the regulation of astrocyte activation. Activation of this pathway is characterized by 
nuclear localization of p65 (132, 134). Immunostaining revealed high NF-κB activation 
upon induction of astrogliosis by p44/WDR77 gene deletion and in astrocytes 
expressing high levels of p21Cip1. P44/WDR77-null Astrocytes that had undergone 
silencing p21Cip1 showed decreased NF-κB activation despite an increase in p65 
expression. While the molecular mechanisms of p21Cip1 modulation of NF-B activity in 
astrocyte are not clear, this result suggests that p44/WDR77 can in part regulate NF-B 
activity through modulation of p21Cip1 expression. The growing evidence suggest that 
cell cycle control systems directly regulate the induction of reactive gliosis raising the 
possibility that signaling changes induced by astrocyte activation in cytokines such as 
TNF- might induce subsequent NF-B activation (132, 246-248). Furthermore, we 
demonstrated that over expression of human p21Cip1 in astrocytes did not increase p65 
expression and nuclear localization to the levels generated by p44/WDR77 gene 
deletion, suggesting that p44/WDR77 has additional regulatory controls over NF-B 
activity.  
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Chapter VII: 
Aim 4: To examine the role of NF-B activation in 
astrocyte activation induced by the loss of 
p44/WDR77. 
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A. Down regulation of NF-B activity in astrocytes completely recovers the 
decrease in cell growth induced by p44/WDR77 deletion. 
 
AI. Rationale: 
Astrocytic proliferation is a fundamental component in glial scar formation which 
can hinder patient recovery from severe astrogliosis (94, 95, 99 -103).  Despite decades 
of research into astrocytic function the molecular mechanism of astrocytic proliferation 
remain unclear (50). We found that the loss p44/WDR77 in astrocytes induces a 
dramatic decrease in cell growth (Figure 22), and that this growth could be partially 
recovered through down regulation of p21Cip1 expression (Figure 28B). Additionally the 
experiments depicted in Figure 29 illustrate that NF-B, a transcription factor implicated 
in astrocytic proliferation, is up regulated during astrocyte activation induce by 
p44/WDR77 gene deletion and that NF-B activity is positively modulated by p21Cip1 
(249, 250). While p21Cip1 is a potent regular of cell growth and cycle, this finding also 
suggests p44/WDR77 might influence astrocyte growth directly through the modulation 
of NF-B activity.  
 
AII. Experimental Design: 
To determine the roles of NF-B in astrocytes activation induced by the loss of 
p44/WDR77, p44/WDR77loxP/loxP astrocytes were infected with lentivirus expressing (i) 
nontargeting control; (ii) p65 shRNA; (iii) p21Cip1 + p65 shRNA (Figure 32A). Four day 
later the astrocytes were infected with either Ad-CMV-GFP or Ad-CMV-Cre–GFP to 
generate 6 cell lines (WT: Control-GFP, p65 shRNA-GFP, p21Cip1 + p65 shRNA-GFP, 
MT: Control-Cre, p65 shRNA-Cre, p21Cip1-Cre + p65 shRNA-Cre) (Figure 34A).  Then 
growth of these cell lines was examined by plating the cells in a 24-well plate and cells 
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were counted daily from day 9 to day 13 post adenovirus infection. To confirm 
decreased NF-B activity after p65 shRNA knockdown, MT (p65 shRNA-Cre, p21Cip1-
Cre + p65 shRNA-Cre) and WT (p65 shRNA-GFP, p21Cip1 + p65 shRNA-GFP) 
astrocytes were subject to immunostaining for p65 nine days after adenovirus infection. 
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Figure 34. Experimental design for p65 and p65 + p21Cip1silencing and over-
expressing and p44/WDR77 gene deletion in astrocytes. A, Diagram illustrates of 
p65 and p65 + p21Cip1 silencing in astrocytes. B, Diagram illustrates p65 and p65 + 
p21Cip1 over-expression in astrocytes. 
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To further explore NF-B’s role in astrocytes, p44/WDR77loxP/loxP astrocytes were 
infected with control lentivirus or lentivirus expressing human p65 or human p21Cip1 plus 
human p65. Then cell growth of these three lines was examined by plating the cells to a 
24-well plate and counted everyday from day 9 to day 13 post infection. These 
astrocyte lines were subjected to immunostaining for p65 nine days after infection. 
Cell lysates were collected seven days after virus infection and subjected to 
western blot analysis with anti- p21Cip1, anti-p65 or anti--Actin antibody.   
 
AIII. Results: 
Consistent with the Immunostaining (Figure 32A-F) the Western blot analysis 
revealed increased expression of p65 associated with the loss of p44/WDR77 (Figure 
28A, panel two, lane 5 versus lane 1). The Western blot assay confirmed down 
regulation of p65 in p65 shRNA-GFP and p21Cip1 + p65 shRNA-GFP astrocytes (Figure 
28A, second panel, lanes 3, and 4 versus lane 1). This finding was consistent with the 
Western blot analysis of Control-Cre, p65 shRNA-Cre and p21Cip1 + p65 shRNA-Cre 
which demonstrated a decreased expression of p65 in p65 shRNA-Cre and p21Cip1 + 
p65 shRNA-Cre astrocytes to basil levels (Figure 28A, second panel, lane 7 and 8 
versus lane 5). The shRNA knockdown of p21Cip1 alone did not effect p65 expression 
(Figure 26A second panel, lanes 2 and 6 versus lanes 1 and 5). 
Immunostaining of WT astrocytes (Control-GFP) revealed low levels of p65 
localized to the cytoplasm (Figure 35B and Figure 36B).  The p65 silencing decreased 
these signals (Figure 35H, Figure 36H).  Nine days after infection, the MT (Control-Cre) 
astrocytes expressed high nuclear levels of p65 (Figure 35E), indicative of NF-B 
activation while the MT (p65 shRNA-Cre, p21Cip1 Cre + p65 shRNA-Cre) astrocytes 
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showed with low cytoplasmic expression of p65 in the presence of p44/WDR77 deletion 
(Figures 35K, and 36K).  
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Figure 35.  Down regulation of p65 expression decreases p65 nuclear localization 
and expression induced by p44/WDR77 deletion in astrocytes.  A-F, WT (Control-
GFP) and MT (Control-Cre) astrocytes were stained for nucleus (A and D) and p65 (B 
and E).  The p65 staining signals are merged with nuclear staining (D and F).  G-L, WT 
(p65 shRNA-GFP) and MT (p65 shRNA-Cre) astrocytes were stained for nucleus (G 
and J) and p65 (H and K).  The p65 staining signals are merged with nuclear staining (I 
and L). 
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Figure 36.  Down regulation of p21Cip1 and p65 decreases p65 nuclear localization 
and expression Induced by p44/WDR77 deletion in astrocytes.  A-F, WT (Control-
GFP) and MT (Control-Cre) astrocytes were stained for nucleus (A and D) and p65 (B 
and E).  The p65 staining signals are merged with nuclear staining (D and F). G-L, WT 
(p21Cip1 + p65 shRNA-GFP) and MT (p21Cip1 + p65 shRNA-Cre) astrocytes were stained 
for nucleus (G and J) and p65 (H and K).  The p65 staining signals are merged with 
nuclear staining (I and L). 
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In the growth analysis WT (Control-GFP, p65 shRNA-GFP, p65 + p21Cip1 
shRNA-GFP) and MT (p65 shRNA-Cre, p65 + p21Cip1 shRNA-Cre) astrocytes cells 
continued to increase in cell number until day 12 when they reach confluency. The 
doubling times for WT (Control-GFP, p65 shRNA-GFP, p65 + p21Cip1 shRNA-GFP) are 
26, 23, and 23 hours, respectively. The doubling times for MT (p65 shRNA-Cre, p65 + 
p21Cip1 shRNA-Cre) are 23 and 26 hours, respectively.  In contrast, the MT (Control-
Cre) astrocytes showed only a sight increase in cell number over the course of 5 days 
(Figure 37). 
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Figure 37. Down regulation of p65 restores growth of p44/WDR77 deficient 
astrocytes.  Grow curves of WT (Control-GFP, p65 shRNA-GFP, p21Cip1 + p65 shRNA-
GFP and MT (Control-Cre, p65 shRNA, p21Cip1 + p65 shRNA-Cre) astrocytes.   
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Increased p65 expression in astrocytes expressing human p65 and p21Cip1 plus 
p65 was confirmed by immunostaining (Figure 38B versus Figure 38E, H).  The 
Western blot assays using lysates from these three lines confirmed p65 over expression 
(Figure 29A, middle panel, lane 3 and 4 versus lane 1). Consistent with NF-B known 
role as a positive modulator of p21Cip1 (249, 250), Western blot analysis of p21Cip1 
illustrated an increase in p21Cip1 expression after p65 over expression in astrocytes 
(Figure 29A, top panel, lane 3 versus lane 1). 
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Figure 38. P65 over expression increases NF-B activity.  A-I, Control, p65 and p65 
+ p21Cip1 over expression astrocytes were stained for nucleus (A, D, and G) and p65 (B, 
E and H).  The p65 staining signals are merged with nuclear staining (D, F and I). 
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The growth analysis illustrated significantly decreased growth in p65, and p65 + 
p21Cip1 expressing astrocytes.  The doubling time for the control astrocytes is 24 hours. 
In contrast, the p65, and p65 + p21Cip1 over expressing astrocytes showed only a sight 
increase in cell number over the course of 5 days (Figure 39). 
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Figure 39. P65 over expression decreases growth of astrocytes.  Grow curves of 
Control, p65 over expression, and p65 + p21Cip1 over expression, and p44/WDR77-null 
astrocytes.   
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AIV. Discussion: 
It is not surprising with NF-B ability to influence over 150 genes that activation 
of the canonical or classical NF-κB pathway has been implicated in astrocyte 
proliferation (133, 136, 137, 249, 250). Previous experiments illustrated that the gene 
deletion of p44/WDR77 induces a dramatic decrease in growth of astrocytes (Figure 
21).  While the p65 shRNA did not completely knockdown p65 expression in the WT 
astrocytes, the p65 shRNA and p65 + p21Cip1 shRNA were effective at knocking down 
p65 expression after astrocyte activation induced by p44/WDR77 gene deletion. We 
demonstrated that inhibition of the classical NF-κB pathway activity by the p65 shRNA 
expression can completely recover the decrease in growth of astrocytes induced by loss 
of p44/WDR77.    
Furthermore we demonstrated that NF-B could decrease astrocyte growth to 
the levels seen in p44/WDR77 deficient astrocytes. These finding suggest that 
p44/WDR77 regulates astrocyte proliferation through repressing p65 expression and 
nuclear localization. The molecular mechanisms by which NF-B influences astrocyte 
proliferation still remains unclear however a number pathways including regulation of 
p21Cip1 expression have been implicated in this regulatory process (138, 139). The fact 
that p21Cip1 knockdown only partial recovered astrocyte growth inhibition and that no 
additive effect on cells growth after the knockdown of p65 and p21Cip1 was observed 
infers NF-B has regulatory roles in astrocyte growth that extend beyond p21Cip1.  
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B. The NF-B activity is essential for astrocyte activation induced by p44/WDR77 
gene deletion. 
 
BI. Rationale: 
Astrocytes carry out a vast array of actions critical for healthy CNS function, thus 
it’s not surprising that reactive astrocytes or reactive astrogliosis have primary and 
secondary affects on the disease pathology of the CNS with direct and even grave 
implications on patient outcome (39, 50, 85). We found that p44/WDR77 gene deletion 
in astrocytes induces astrogliosis characterized by the hallmark increase in GFAP.  
Analysis of p44/WDR77 regulation of astrocyte activation revealed that down regulation 
of p21Cip1 expression inhibited reactive astrogliosis induced by p44/WDR77 gene 
deletion. Further examination of this pathway illustrated that down regulation of p21Cip1 
expression was accompanied with decreased p65 nuclear localization. These findings 
are consistent with studies that have implicated the canonical or classical NF-κB 
pathway as a regulator of both beneficial and deleterious astrocytic actions during 
reactive astrogliosis (50, 131, 132, 134, 143). Upon closer investigation of this 
phenomenon, experiments revealed that down regulation of p21Cip1 expression only 
partially recovered astrocyte growth inhibition induced by p44/WDR77 gene deletion, 
while shRNA knockdown of p65 completely recovered the growth inhibition, suggesting 
NF-B activity institutes additional regulatory actions for astrocyte activation induced by 
p44/WDR77 gene deletion.  
 
BII. Experimental Design: 
To examine roles of NF-B in astrocytes activation induced by the loss of 
p44/WDR77, p44/WDR77loxP/loxP astrocytes were infected with lentivirus expressing (i) 
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nontargeting control; (ii) p65 shRNA; (iii) p21Cip1 + p65 shRNA. Four days later 
astrocytes were infected with either Ad-CMV-GFP or Ad-CMV-Cre–GFP to generate 6 
cell lines (WT: Control-GFP, p65 shRNA-GFP, p21Cip1 + p65 shRNA-GFP, MT: Control-
Cre, p65 shRNA-Cre, p21Cip1 + p65 shRNA-Cre) (Figure 34A). Nine days after infection 
astrocytes were immunostained for GFAP. Cell lysates were also prepared from 
astrocytes seven days after adenovirus infection and subjected to western blot analysis 
with anti-GFAP.  
To further explore NF-B roles in astrocytes, WT astrocytes were infected with 
control lentivirus or lentivirus expressing human p65 or human p21Cip1 plus p65 (Figure 
34B). Nine days after viral infection, astrocytes were subject to immunostaining for 
GFAP.  
 
BIII. Results: 
Comparable with earlier findings WT (Control-GFP, p65 shRNA-GFP, and p65 + 
p21Cip1 shRNA-GFP) astrocytes exhibited low levels GFAP and cellular structure of 
nonreactive astrocytes (Figure 30B, Figure 40B, and Figure 41B). Upon loss of 
p44/WDR77 expression (9 days post Ad-Cre infection), the MT (Control-Cre) astrocytes 
expressed higher levels of GFAP (Figure 30E), indicative of astrocyte reactivity.  While 
the MT (p65 shRNA-Cre, and p65 + p21Cip1 shRNA-Cre) astrocytes despite the loss of 
p44/WDR77 showed low levels GFAP and cellular structure of nonreactive astrocytes 
(Figure 40E, and Figure 41E). This finding was confirmed by the Western blot analysis 
that demonstrates a hallmark increase of GFAP in MT (Control-Cre) astrocytes while 
the MT (p65 shRNA-Cre, and p65 + p21Cip1 shRNA-Cre) astrocytes maintain basil level 
of GFAP expression (Figure 28A, third panel, lane 5 versus lanes 7 and 8). 
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Figure 40. Down regulation of p65 inhibits astrocyte activation induced by 
p44/WDR77 deletion in astrocytes.  A-F, WT (p65 shRNA GFP) and MT (p65 shRNA 
Cre) astrocytes were stained for nucleus (A and D) and GFAP (B and E).  The GFAP 
staining signals are merged with nuclear staining (C and F). 
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Figure 41. Down regulation of p65 + p21Cip1 inhibits astrocyte activation induced 
by p44/WDR77 deletion in astrocytes.  A-F, WT (p65 + p21Cip1 shRNA-GFP) and MT 
(p65 + p21Cip1 shRNA-Cre) astrocytes were stained for nucleus (A and D) and GFAP (B 
and E).  The GFAP staining signals are merged with nuclear staining (D and F).  The 
GFAP staining signals are merged with nuclear staining (C and F). 
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Consistent with prior studies (50, 133, 136, 137) that suggest NF-B is a 
regulator of astrocyte activation, we found that p65 and p65 + p21Cip1 over expression 
increased GFAP expression (Figure 42E, and Figure 43E), while the control astrocytes 
maintained low levels GFAP and cellular structure of nonreactive astrocytes (Figure 
42B).    
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Figure 42. P65 over expression leads to increased GFAP expression in 
astrocytes.  A-F, Control and p65 over expression astrocytes were stained for nucleus 
(A and D) and GFAP (B and E).  The GFAP staining signals are merged with nuclear 
staining (C and F). 
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Figure 43. P65 + p21Cip1 over expression leads to increased GFAP expression in 
astrocytes.  A-F, Control and p65 + p21Cip1 over expression astrocytes were stained for 
nucleus (A and D) and GFAP (B and E).  The GFAP staining signals are merged with 
nuclear staining (C and F). 
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BIV. Discussion:  
Other studies utilizing transgenic mice expressing a dominant negative (dn) form 
of the inhibitor of Bdriven by GFAP promoter demonstrated that the loss of NF-B 
activity following spinal cord injury resulted in decreased GFAP expression and glial 
scaring (131). This alteration in astrocyte activation was accompanied with a reduction 
in astrocytic production of proinflammatory chemokines and cytokines, such as 
CXCL10, CCL2 (131).  This study, along with a multitude other studies have suggested 
astrocytic NF-B plays a role in reactive astrogliosis and neuropathology (50).  
P44/WDR77 gene deletion in astrocyte induces a striking increase astrogliosis in 
the MT mouse brain and astrocytic culture. This induction of astrocytic activation is 
associated with a significant increase p21Cip1 expression and NF-B activation 
characterized by p65 nuclear localization. We found that repression of p21Cip1 
expression after p44/WDR77 deletion inhibited astrocyte activation and was 
accompanied with decreased p65 nuclear localization.  While p21Cip1‘s role in activation 
of astrocyte and NF-B is not well understood, studies of other cell cycle regulators 
have implicated cell cycle control systems as modulators of astrocyte activation, thus 
could induce secondary effects to induce p65 nuclear localization (50, 132, 246-248). 
Growth analysis of p44/WDR77 deficient astrocytes illustrated that NF-B activity 
institutes additional regulatory actions not mediated by p21Cip1, through completely 
recovered astrocyte growth after p65 knockdown, while p21Cip1 knockdown only partially 
recovered astrocyte growth.  
Consistent with NF-B implications in astrocyte activation, immunostaining 
revealed the induction of astrogliosis by p44/WDR77 gene deletion characterized by 
increased GFAP expression only in astrocytes exhibiting p65 nuclear localization (50).   
Furthermore we confirmed NF-B ability to induce astrocytes activation independent of 
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the p44/WDR77 status through the induction of over expression of human p65, 
suggesting that p44/WDR77 influences astrocyte activation through the regulation of 
p65 expression and nuclear localization.  However neither p65 or p65 + p21Cip1 over 
expression reached the levels of GFAP expression generated by p44/WDR77 deletion 
in astrocytes. This result indicates there are other changes induced by the loss 
p44/WDR77 in astrocytes, thus prompting further study into p44/WDR77 involvement in 
astrocyte activation.   
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Chapter VII:  
Summary and Future Directions 
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Chapter VII: Summary and Future Directions 
Astrocytes, the most abundant cell type in the brain, were long underappreciated 
as they were thought to be merely a supportive component of the CNS, and their 
reactive state viewed simply as a marker for CNS disease (25, 38). The past few 
decades of research has drastically altered this view leading to a deepened interest on 
their biological importance under normal and pathologic conditions (39). Active roles for 
astrocytes in numerous functions essential for proper and healthy activity of the CNS 
have been established, some of which are providing energy metabolites to neurons, 
enhancing neuronal survival under stressed conditions, modulating extracellular 
balance of ions, and synaptic transmission (18, 40-42). Insults to the CNS initiates 
series of metabolic and morphological changes in astrocytes commonly referred to as 
reactive gliosis or astrogliosis (43-47).  Despite decades of research, many of 
fundamental questions about the molecular mechanisms that lead to reactive astrocytes 
are just beginning to lead to a better understanding of overall CNS pathology (50). 
Preliminary studies revealed a striking increase in reactive astrogliosis and 
cellular apoptosis in the brains of p44/WDR77-deficient mice.  Additionally astrogliosis 
was only observed in astrocytes that had lost p44/WDR77 expression (Figure 12). This 
finding combined with prior studies in our laboratory that illustrate p44/WDR77 plays 
important roles in the proliferation and differentiation of prostate epithelial cells, suggest 
that p44/WDR77 conducts regulatory functions in cellular differentiation and possibly 
activation of astrocytes (181). Given astrocytes vast clinical importance this warrants 
farther exploration into p44/WDR77 regulatory actions in activation astrocytes. 
Astrocytes were isolated from mouse (p44loxP/loxP) brain and immortalized with 
adenovirus E6/E7. The p44/WDR77 gene was deleted by adenovirus-mediated Cre 
expression.  Using this cell culture system, we demonstrated p44/WRD77 is essential 
for growth of astrocytes and loss of p44/WDR77 expression in astrocytes leads to 
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dramatic changes in cellular structure and increased expression of GFAP, indicative of 
astrogliosis (Figure 20 – 24).  Thus, p44/WDR77 prevents astrogliosis in the brain.   
Recent studies have suggested that the AR-target gene p21Cip1 directly effects 
astrocyte activation (140, 141, 152, 172). This finding correlated with increased p21Cip1 
expression in MT mice brains found in our gene array of whole brains from MT and WT 
mice. Further analysis of this pathway revealed the loss of p44/WDR77 in astrocytes 
generated a significant increase in p21Cip1 expression and the inhibition of this increased 
expression inhibits astrocyte activation induced by p44/WDR77 gene deletion (Figure 
25 – 31). While the mechanistic actions of p21Cip1 in reactive gliosis remain incompletely 
characterized, there is growing evidence that cell-cycle control systems institute 
regulatory functions in reactive gliosis, (246-248). While a more detailed analysis is 
needed to confirm p44/WDR77 regulation of astrocyte cell cycle this coupled with our 
findings puts fourth that p44/WDR77 modulates astrocyte activation by indirectly 
inducing cycle changes through effecting p21Cip1 expression (Figure 44). This doesn’t 
preclude other modulatory actions of p21Cip1 such as positive modulatory effects on NF-
B activation a pathway long implicated in gliosis; represent a possible contributing 
mechanism of action (140, 141). 
Activation of the canonical or classical NF-κB pathway has been implicated in 
the regulation of astrocyte activation.  Activation of this pathway is characterized by 
nuclear localization of p65 (132, 134).  Examination of this pathway in astrocytes after 
p44/WDR77 gene deletion revealed increased activation of the classical NF-κB pathway 
(Figure 32).  The knockdown of p65 in p44/WDR77-deficient astrocytes reduced GFAP 
expression to basal levels and suppressed phenotypes of activated astrocytes induced 
by the deletion of p4/WDR77 gene.  While p44/WDR77 regulation of NF-B activity is 
largely unexplored, p44/WDR77’s ability to act as a cofactor for GR, a known 
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transrepressor of p65 activity, represents a possible mechanism of action and area that 
warrants further study (238). 
The inhibition of increased p21Cip1 expression decreased p65 nuclear 
localization.  Over expression of p21Cip1 enhanced p65 expression and over expression 
of p65 also increased p21Cip1 expression.  These observations suggest that p21Cip1 and 
NF-kB are cross-linked.  The molecular mechanisms of this cross-talk in astrocyte are 
not clear.  This modulatory affect might be a secondary action induced by changes in 
cell cycle control systems that institute regulatory functions in reactive gliosis that in turn 
can create signaling changes in cytokines such as TNF- that can invoke NF-B activity 
(132, 246-248).  Other studies utilizing transgenic mice expressing a dominant negative 
(dn) form of the inhibitor of Bdriven by GFAP promoter demonstrated that the loss of 
NF-B activity following spinal cord injury resulted in decreased GFAP expression and 
glial scarring (131). This alteration in astrocyte activation was accompanied with a 
reduction in astrocytic production of proinflammatory chemokines and cytokines, such 
as CXCL10, CCL2 (131), which might affect p21Cip1 expression.  
The data in this study puts forth the model that p44/WDR77 can influence the 
activational states of astrocytes through independently and jointly augmenting the 
expression and activity of p21Cip1 and NF-B (Figure 44). 
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Figure 44. Model of p44/WDR77 role is astrocyte activation. 
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While many of detailed mechanisms of astrocyte activation remain to be eluted, 
a multitude of pathways have been implicated in astrocyte activation (50).  Two such 
pathways are illustrated in androgen and glucocorticoid ability to down-regulate reactive 
gliosis after neural injury (227-229).  P44/WDR77’s gift to orchestrate modulatory 
effects over AR- and GR-dependent gene expression as cofactor represents a possible 
means to regulate astrocyte activation (180).  It is also possible that p44/WDR77 might 
interact and function with other DNA-binding proteins in astrocytes.  Further studies are 
needed to clarify p44/WDR77 mechanistic actions in astrocytes. 
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